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Summary 
 
Ultraviolet (UV) irradiation and UVB in particular, is the major environmental risk factor for the 
development of skin cancer. Furthermore, an increasing body of evidence supports a role for 
cutaneous human papillomaviruses (HPVs) in combination with UV irradiation in the development of 
cutaneous squamous cell carcinoma. Moreover, cutaneous HPV E6 proteins have been described to 
indirectly influence pathways controlled by p53, to inhibit UV-induced apoptosis and to prolong the 
life span of keratinocytes, the natural host of all HPVs.  
The present study identified the LIM protein Ajuba as a novel interaction partner of the E6 protein of 
the beta2 HPV23, the gamma1 HPV4 and the gamma11 HPV148. These E6 proteins were shown to 
directly interact with Ajuba both in vitro and in vivo as well as to co-localise with Ajuba in the 
cytoplasm. Furthermore, the E6 proteins of HPV23 and HPV148 showed a coincidental decrease in 
protein expression together with their interaction partner Ajuba upon DNA damage induction and 
siRNA-mediated Ajuba knockdown. This knockdown also revealed that the p53 protein was involved 
in the regulation of Ajuba and HPV E6 protein levels. On the other hand, Ajuba co-accumulated 
following overexpression of the cutaneous E6 proteins, further pointing to a close interaction of both 
proteins in vivo. A trimeric complex formation between p53, Ajuba and HPV148 E6 was additionally 
discovered, which did not take place with HPV23 E6. Moreover, p53 was shown to co-localise and to 
interact directly with HPV148 E6 in vitro and in vivo, even in the absence of Ajuba. A functional 
luciferase reporter assay revealed a strong repression of p53 activity in the presence of HPV148 E6, 
demonstrating an impairment of the transactivation activity of p53. This observation could however 
not be reported for HPV23 E6.  
In summary, the present study identified the LIM protein Ajuba as a novel interaction partner of 
cutaneous E6 proteins. Additionally, it demonstrated for the first time that the p53 protein not only 
binds to cutaneous HPV E6 proteins in vitro, but also interacts and co-localises with HPV148 E6 in 
vivo, subsequently repressing p53 activity. These findings suggest a novel regulatory mechanism 
elicited by cutaneous E6 proteins and further strengthen the hypothesis that cutaneous HPVs can act 
as co-factors in the development of skin cancer. 
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Zusammenfassung 
 
Ultraviolette (UV) Strahlung und im Besonderem UVB, gilt als Hauptursache für die Entstehung von 
Hautkrebs. Darüber hinaus gibt es eine wachsende Anzahl von Studien, die zeigen, dass kutane 
Humane Papillomviren (HPV) zusammen mit UV-Strahlung an der Entstehung von kutanen 
Plattenepithelkarzinomen beteiligt sind. Zudem wurden kutanen HPV E6 Proteinen verschiedene 
Eigenschaften zugeschrieben wie z.B. die indirekte Einflussnahme auf Signalwege, die von p53 
kontrolliert werden, die Fähigkeit UV-induzierte Apoptose zu hemmen, sowie die Lebensspanne von 
Keratinozyten, den natürliche Wirtszellen aller HPV Typen, zu verlängern. 
Die vorliegende Studie hat einen neuen Interaktionspartner für die E6 Proteine des Beta2-HPV Typs 
23, des Gamma1-HPV Typs 4 und des Gamma11-HPV Typs 148 identifiziert: das LIM Protein Ajuba. Es 
konnte gezeigt werden, dass die erwähnten E6 Proteine mit Ajuba direkt in vitro wie auch in vivo 
interagieren und mit Ajuba im Zytoplasma ko-lokalisieren. Ferner wurde gezeigt, dass DNS 
Schädigung sowie die siRNA-vermittelte Abschaltung von Ajuba zu einer simultanen Verringerung der 
Proteinexpression bei den E6 Proteinen von HPV23 und HPV148 sowie Ajuba führt. Außerdem wurde 
durch die RNA-Interferenzversuche deutlich, dass das p53 Protein an der Regulierung der 
Proteinexpression von Ajuba und den E6 Proteinen beteiligt ist. Andererseits wurde die Anreicherung 
von Ajuba nach Überexpression der E6 Proteine festgestellt, sodass davon auszugehen ist, dass beide 
Proteine in einem physiologisch engen Zusammenhang stehen. Überdies wurde die Entstehung von 
einem Komplex aufgedeckt, der sich aus den drei Proteinen p53, Ajuba und HPV148 E6 
zusammensetzt. Dies konnte im Falle von HPV23 E6 nicht gezeigt werden. Zudem wurde eine 
Ko-Lokalisation von p53 und HPV148 E6 beschrieben. Es wurde zum ersten Mal gezeigt, dass beide 
Proteine in vitro und in vivo miteinander interagieren, auch wenn Ajuba nicht präsent ist. In 
funktionalen Versuchen konnte gezeigt werden, dass die Aktivität von p53 allein durch die 
Anwesenheit von HPV148 E6 stark unterdrückt wird. Diese neue Eigenschaft von HPV148 E6 konnte 
für HPV23 E6 nicht festgestellt werden. 
Zusammenfassend wurde in der vorliegenden Arbeit ein neuer Interaktionspartner für kutane HPV E6 
Proteine beschrieben. Zusätzlich wurde zum ersten Mal gezeigt, dass das p53 Protein nicht nur 
kutane E6 Proteine in vitro binden kann, sondern auch dass es mit ihnen in vivo interagiert und 
ko-lokalisiert, was unweigerlich zu einer Repression der p53-Aktivität führt. Diese Erkenntnisse 
weisen auf einen neuen Regulationsmechanismus von kutanen HPV E6 Proteinen hin und bekräftigen 
ferner die Hypothese, dass kutane HPV Typen als Ko-Faktoren an der Entstehung von 
Hautkrebserkrankungen beteiligt sind.  
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S e c t i o n 1 
 
Introduction 
 
1.1 Infectious agents as a cause of cancer 
For a long time cancer has represented one of the major causes of death worldwide 
accounting for approximately 13% of all annual deceases (around 7.6 million) [World Health 
Organization (WHO), 2013]. Cancer development itself is a multistep process. It is mostly caused by 
somatic mutations and does not arise from a single mutation, but from the accumulation of several 
distinct alterations [Vogelstein and Kinzler, 1993]. These can release the cells from normal growth-
control mechanisms and result in unconfined cellular proliferation, enabling the cancer cells to 
become tumourigenic and, in an ultimate step, malignant [Hanahan and Weinberg, 2011]. The 
development of cancer can be caused by spontaneous mutations, but it is strongly favoured in the 
presence of chemical, physical, or biological carcinogens. While radiation - both ionizing and 
ultraviolet (UV) - is a physical carcinogen, chemical carcinogens include tobacco smoke, asbestos or 
toxins. Additionally, biological carcinogens such as infections with certain bacteria or viruses 
represent another risk factor [Dalton-Griffin and Kellam, 2009; Martin and Gutkind, 2008]. 
The discovery of viruses being potential infectious agents goes back to the late 19th century, 
when the first filtration devices that were able to remove cells and bacteria were developed. At that 
time the first virus, the tobacco mosaic virus (TMV), was discovered [Lecoq, 2001]. So-called “tumour 
viruses” have been known since the discovery of the avian leukemia virus (ALV) in 1908, but back 
then leukemia did not belong to a tumour-causing virus [Ellerman and Bang, 1908; Epstein, 1971]. In 
1911 Peyton Rous showed that a solid tumour of the fowl could be transmitted to other previously 
healthy animals using a cell-free, filtered extract from chicken sarcomas [Rous, 1911]. This 
tumour-inducing agent was later identified as a virus, now known as the Rous sarcoma virus (RSV). 
This discovery for the first time clearly demonstrated that malignant tumours can be induced by viral 
infection. Since that time, many other tumour-inducing viruses were identified and characterised, 
like the Shope papillomavirus found in cottontail rabbits, later termed the cottontail rabbit 
papillomavirus, CRPV [Shope and Hurst, 1933]. Other examples e.g. in mice [Bittner, 1942; Gross, 
1951] and non-human primates [Sweet and Hilleman, 1960] were also described. Shortly after the 
discoveries of tumour viruses in animals, the first oncogenic human virus, the Epstein-Barr virus 
(EBV), was discerned in the 1960s [Epstein et al., 1964].  
An estimated 18% of the worldwide cancer burden can be attributed to infections [Parkin, 
2006]. To date, these infectious agents include at least six viruses and several bacteria. Infections 
with the hepatitis B and C viruses (HBV, HBC) are well-recognised risk factors for the development of 
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cirrhosis and liver cancer [Perz et al., 2006]. The Epstein-Barr virus, also known as human 
herpesvirus 4 (HHV-4), is associated with B-cell lymphoproliferative diseases and nasopharyngeal 
carcinomas [Raab-Traub, 1992, 2012]. Another herpesvirus, HHV-8 or Kaposi's sarcoma-associated 
herpesvirus (KSHV), has been linked to Kaposi’s Sarcoma and primary effusion lymphomas [Antman 
and Chang, 2000; Damania, 2004]. Infections with the human T-cell lymphotropic virus (HTLV-1), a 
human retrovirus, are associated with adult T-cell leukemia (ATL) [Matsuoka and Jeang, 2007; Poiesz 
et al., 1980]. One bacterial example for infection-induced carcinogeneses is Helicobacter pylori, 
which is linked to the development of gastric cancers [Lax and Thomas, 2002; Pagano et al., 2004]. 
Apart from EBV, human papillomaviruses (HPVs) are one of the best studied examples of human 
tumour viruses. HPVs are etiologically linked to anogenital cancers [Pagano et al., 2004; zur Hausen, 
2002]. Almost all cervical tumours contain HPV DNA and can thus be attributed to HPV infection 
[Parkin and Bray, 2006; Walboomers et al., 1999]. In 2008, cervical cancer was considered the second 
most common cancer in women worldwide with annually 530.000 to 600.000 new cases and 275.000 
deaths [de Martel et al., 2012; Ferlay et al., 2010]. That is why further investigations of the 
mechanisms of HPVs remain important: first, for a better understanding of the viruses and second, to 
be able to fight them in a more sophisticated way. 
 
1.2 Papillomaviruses 
Papillomaviruses (PVs) are a diverse group of small non-enveloped DNA viruses that are 
distributed in different animal species, primarily in vertebrates ranging from birds to humans 
[Antonsson and Hansson, 2002]. Examples for mammals from which papillomaviruses were isolated 
are cattle [Campo, 1997], reindeer [Moreno-Lopez et al., 1987], domestic cats [Sundberg et al., 2000] 
and horses [O'Banion et al., 1986]. Additionally, a growing number of novel papillomaviruses is being 
identified in other hosts [Antonsson and McMillan, 2006; Gottschling et al., 2008; Schulz et al., 2009; 
Schulz et al., 2012]. Specific PVs can induce cancerous lesions in cattle, dogs or domestic rabbits 
[Campo, 2002]. However, by far the largest number of papillomaviruses was found in humans, 
encompassing over 150 distinct types [Bernard et al., 2010]. Papillomaviruses are highly 
epitheliotropic pathogens and can induce diverse lesions in the stratified squamous epithelia of skin 
and mucosa. In addition, HPVs were classified as human carcinogens [Schiffman et al., 2007]. 
 
1.2.1 Human papillomaviruses 
Human papillomaviruses cause diseases ranging from benign warts and other benign 
epithelial tumours, which may regress spontaneously [van Duin et al., 2002], to malignant cancers. 
The viruses can be classified into different groups. One group, the genital HPVs infect mucosal 
keratinocytes of the (ano)genital region and can be further divided into two subgroups according to 
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their oncogenic potential: the “high-risk” and “low-risk” types. Low-risk HPV types like HPV6 and 
HPV11 can cause low-grade lesions such as genital warts (Condylomata acuminata) and are rarely 
present in malignancies [Wilczynski et al., 1993]. High-risk HPV types, on the other hand, are 
associated with the development of cervical intraepithelial neoplasia (CIN) and are therefore 
recognised as the causative agent of cervical carcinoma and head and neck cancer [Bosch et al., 
2002; Gillison et al., 2012; Schiffman et al., 2007]. Several studies showed that the prevalence of HPV 
DNA in cervical carcinomas is higher than 99% [Bosch et al., 1995; Walboomers et al., 1999] with 
HPV16 and HPV18 being the two most abundant types that are detected in 50% and 20% of all 
cervical cancers, respectively. Fifteen HPV types were classified as high-risk and oncogenic by the 
World Health Organization (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) [Muñoz et al., 
2003]. Apart from the well-studied genital types, the large group of cutaneous HPVs can be 
discerned, some of whose representatives are proposed to play a role in the development of skin 
cancers [Harwood and Proby, 2002; Nindl et al., 2007]. 
 
1.2.2 HPV classification 
As already mentioned HPVs infect keratinocytes of mucosa and skin where they can cause a 
variety of symptoms starting from common warts (Verruca vulgaris), palmar and plantar warts to 
cervical cancer [Doorbar, 2005]. The life cycle of HPVs is directly linked to the epithelial cell 
differentiation of the host, rendering them very host specific [Fehrmann and Laimins, 2003]. PVs 
constitute a separate taxonomic family, the Papillomaviridae, and are generally grouped into 
mucosal/genital and cutaneous types [de Villiers et al., 2004]. Based on sequence homologies of their 
L1 nucleotide sequences HPVs have been classified into five genera: alpha-, beta-, gamma-, mu- and 
nu-papillomaviruses [Bernard et al., 2010; Doorbar et al., 2012]. This classification was further 
validated by using a more complex analysis including the E1, E2 and L1 amino acid sequences 
(Fig. 1.1) [Gottschling et al., 2011]. The highlighted HPV types in figure 1.1: HPV117 (Alpha PV), 
HPV23 and -118 (Beta PV) HPV4, -134 and -148 (Gamma PV) were the ones used for the experiments 
in this thesis. Most of them have been recently isolated [Köhler et al., 2010; Köhler et al., 2011]. 
The genera have different biological properties. Genitally transmitted HPVs which infect the 
mucosa of the cervix belong to the alpha papillomaviruses, i.e. the alpha genus, which is the largest 
group within the characterised HPVs. Examples are the high-risk types HPV16 and HPV18 and the 
low-risk types HPV6 and HPV11. Members of the remaining four genera (beta, gamma, mu, and nu) 
were shown to induce cutaneous lesions in humans and are not as well characterised [de Villiers et 
al., 2004; zur Hausen, 2002]. Nonetheless, some beta-PVs, which are innocuous for the general 
population, are associated with the development of skin cancer in certain individuals. These patients 
are mostly immunocompromised organ transplant recipients (OTR) or suffer from the rare hereditary 
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disease Epidermodysplasia verruciformis (EV), which is characterised by an increased susceptibility to 
specific HPV types and is linked to the development of non-melanoma skin cancer (NMSC) [Doorbar, 
2005; Harwood et al., 2004; Lutzner, 1978; Ramoz et al., 2002].  
 
Figure 1.1: Phylogenetic tree of different papillomavirus types classified by genera. 
The phylogenetic tree is based on an E1-E2-L1 amino acid sequence analysis of the indicated PV types. PV taxa 
are indicated in genera and species according to Bernard et al. [2010]. The groups are coloured in red (Alpha 
and Omikron PVs), green (Beta, Gamma and Xi PVs), blue (Delta and Zeta PVs), and ochre (Lambda and Mu 
PVs), respectively. Red circles indicate the HPV types HPV117 (Alpha PV), HPV23 and 118 (Beta PV), HPV4, 134, 
and 148 (Gamma PV). These HPV types were used for the experiments in this thesis. Figure adapted from 
Gottschling et al. [2011] 
 
Furthermore, epidemiological studies have shown that infections with cutaneous HPVs of 
the beta genus may develop into keratotic skin lesions and even progress to squamous cell 
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carcinoma (SCC) in both immunocompetent and immunosuppressed individuals in combination with 
UV exposure, which acts as an immunosuppressive agent [Bouwes Bavinck et al., 2007; de Koning et 
al., 2007; Jackson and Storey, 2000; Murphy, 2009]. 
 
1.2.3 HPV genome organisation  
Human papillomaviruses, similarly to other PVs, have a double-stranded circular genome of 
approximately 8kb. Cellular histones are associated with the viral DNA and form a chromatin-like 
structure. Most of the HPV genomes contain eight open reading frames (ORFs), whose genetic 
information is located on only one of the two DNA strands [Favre et al., 1997] and which are 
transcribed as polycistronic messenger RNAs (mRNAs) [Fehrmann and Laimins, 2003]. In benign and 
productive infections, HPV DNA is maintained as an episome and is only rarely integrated into the 
host genome. High-risk HPV genomes, on the other hand, are often found integrated into the 
genomes of cervical cancer cells, highlighting the crucial role for viral integration into the host 
genome during carcinogenesis [Cullen et al., 1991; Stanley, 2012].  
Functionally, the HPV genome is arranged in three parts: (1) the non-coding long control 
region (LCR), also referred to as upstream regulatory region (URR), (2) the early region encoding the 
early regulatory proteins (E1, E2, E4, E5, E6, and E7), and (3) the late region coding for the major and 
minor capsid proteins L1 and L2, respectively (Fig. 1.2) [Favre et al., 1997].  
 
 
Figure 1.2: Schematic overview of the genome organisation of mucosal and cutaneous HPV types. 
The genome comprises the long control region (LCR) and up to eight genes that are expressed in different 
stages of the viral life cycle. The early genes are shown in red and green, the late genes in ochre. The missing E5 
ORF in cutaneous HPV types (right) is highlighted. Arrow heads designate the positions of the early (PE) and 
late (PL) promoters. PAE and PAL indicate the positions of the early and late polyadenylation sites. Figure 
adapted from Doorbar et al. [2012]. 
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The LCR is located between the L1 and E6 ORFs. It contains the origin of replication and 
binding sites for different transcription factors of viral and host origin, thus being able to display 
regulatory functions [Doorbar, 2006]. E1 binds to the viral origin of replication and, with the help of 
E2, initiates DNA unwinding for the replication of the viral genome [Wilson et al., 2002]. The E4 
protein is expressed from spliced mRNAs encoding an E1^E4 fusion protein containing five additional 
amino acids from the N-terminus of E1. E4 has been suggested to be involved in the alteration of the 
cytoskeleton network [Doorbar et al., 1991; Fehrmann and Laimins, 2003]. E5, E6 and E7 of high-risk 
HPVs are considered viral oncogenes whose expression induces transformation and cell 
immortalisation [Zheng and Baker, 2006]. The genes of the late region, L1 and L2 encode both 
structural proteins, which assemble into the viral capsid [Florin et al., 2002].  
The high-risk E5 gene encodes a membrane-associated protein with a weak transforming 
activity [Leptak et al., 1991; Zhang et al., 2002]. Upon viral DNA integration the E5 coding sequence is 
often deleted [Schwarz et al., 1985]. While all genital HPV types encode E5, its general absence is a 
characteristic feature of cutaneous HPV types (Fig. 1.2) [Chan et al., 1995]. The mandatory proteins 
to induce immortalisation and malignant transformation of cells are E6 and E7. High-risk E6 and E7 
bind to and degrade the tumour suppressors p53 and members of the retinoblastoma family of 
proteins (pRb), respectively. The expression of the E6 and E7 oncogenes is required to maintain the 
transformed phenotype [Goodwin and DiMaio, 2000; Munger et al., 2004; Muñoz et al., 2006]. In 
contrast to high-risk E6 and E7 proteins, the function of their cutaneous counterparts is still not well 
characterised. Nevertheless, several studies showed that cutaneous HPV E6 proteins degrade the 
pro-apoptotic protein Bak and thus inhibit apoptosis after UVB-induced DNA damage, which is in part 
dependent on p53 expression [Jackson et al., 2000; Simmonds and Storey, 2008; Underbrink et al., 
2008; Ziegler et al., 1994]. The E6 and E7 proteins of the beta-PV HPV38 were shown in particular to 
have transforming activities by activating telomerase and inactivating pRb, which led to an extension 
of cell survival [Bedard et al., 2008; Caldeira et al., 2003].  
 
1.3 HPV and cancer 
Infections with mucosal high-risk HPVs are causally linked to the development of cervical 
cancer [Bosch et al., 2002]. But not only genital HPV types have been associated with cancer. Certain 
cutaneotropic HPV types have been linked to the development of non-melanoma skin cancer, 
especially in patients with the rare genetic disorder Epidermodysplasia verruciformis [Favre et al., 
1997; Jablonska et al., 1972] and in organ transplant recipients who undergo systemic 
immunosuppression [Ulrich et al., 2008]. Nonetheless, the exact oncogenic potential of cutaneous 
HPV types remains debatable, partly because they were less studied than the genital types but also 
due to the large number and diversity of cutaneous types. 
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1.3.1 HPV and Epidermodysplasia verruciformis  
The first evidence for HPV playing a role in SCC development was found in patients suffering 
from the rare hereditary disorder Epidermodysplasia verruciformis (EV) [Jablonska et al., 1972]. EV is 
characterised by persistent disseminated wart-like skin lesions predominantly on sun-exposed sites, 
which result from unusually high susceptibility to infections with specific HPV types from the beta 
genus. In about 30% of all cases, these lesions ultimately progress to cutaneous SCC [Orth et al., 
1978; Orth, 2006]. Several beta-HPV types were previously isolated from these lesions and are 
therefore referred to as “EV HPV types”. Mainly high copy numbers of episomal viral genomes of the 
beta1 HPV types 5 and 8 were detected in about 90% of cutaneous SCC [Majewski and Jablonska, 
2006; Orth, 2006]. Individuals suffering from EV carry nonsense mutations in the two adjacent genes 
EVER1 and EVER2. The gene products encode integral membrane proteins located in the 
endoplasmic reticulum. Since these proteins belong to the family of transmembrane channel-like 
(TMC) proteins, the gene names have however been changed from EVER1 and EVER2 to TMC6 and 
TMC8, respectively [Lazarczyk et al., 2008; Ramoz et al., 2002]. TMC6 and TMC8 were found to 
interact with the zinc transporter 1 (ZnT-1) protein and were thus hypothesised to be involved in the 
cellular regulation of zinc homeostasis. The complex formed by these proteins can inhibit the activity 
of transcription factors, such as AP-1, which is a central transcription factor in the HPV life cycle. 
Although, HPV16 E5 was found to interact with endogenous TMC and ZnT-1 and to counteract their 
down-regulation, this mechanism does not apply to the EV HPV types which (lie all cutaneous types) 
lack the E5 ORF [Bravo and Alonso, 2004; Lazarczyk et al., 2008; Lazarczyk et al., 2009]. It is therefore 
suggested that the mutation in TMC in EV HPV types that renders the protein non-functional, may 
alleviate the host restriction and promote viral replication [Lazarczyk et al., 2008]. 
 
1.3.2 HPV and Non-melanoma skin cancer  
Non-melanoma skin cancer (NMSC) is the most prevalent malignancy in fair-skinned 
populations world-wide. It includes two main histologic types: basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) with actinic keratosis (AK) as precursor lesions [Harwood et al., 2000; 
Ko et al., 1994; Nindl et al., 2007; Pfister, 2003]. UV radiation is the major environmental risk factor 
for the development of epithelial skin cancers, which is e.g. reflected in tumour localisation at 
predominantly sun-exposed sites. However, UV is not the only risk factor. Other parameters 
contributing to skin cancer are genetic predisposition, the immune status and, in the context of HPV, 
viral infections [Corona et al., 2001; Dubina and Goldenberg, 2009]. Still, UV irradiation, in particular 
UVB (ranging from 280-320nm), can lead to the induction of skin cancer through the direct formation 
of cyclobutane dimers and transitions in DNA. Hence, the constitutive accumulation of mutations 
combined with immunosuppression can progress into epithelial skin cancer [Muñoz et al., 2006]. 
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Furthermore, malfunctioning apoptosis or DNA repair mechanisms can as well result in the 
accumulation of genetic mutations and thus lead to epithelial skin cancer development [Rastogi et 
al., 2010]. 
Additionally, UVB has three other effects on the skin which can together contribute to the 
formation of skin cancer. On top of the aforementioned effect of direct mutation of keratinocyte 
DNA, it upregulates gene expression of e.g. HPV20, -23 and -77 [Purdie et al., 1999; Ruhland and de 
Villiers, 2001], induces tolerance to antigens and suppresses the immune system, via a process 
referred to as photoimmunosuppression [Ichihashi et al., 2003; Schwarz, 2002]. Removal of 
UV-induced DNA lesions through DNA repair mechanisms was shown to result in the regression of 
UV-induced immunosuppression [Kripke et al., 1992; Schwarz, 2005].  
The tumour suppressor p53 is also known to be involved in skin carcinogenesis [Nakazawa et 
al., 1994]. UV-induced p53 mutations are found in up to 50% of actinic keratoses, a premalignant 
stage of SCC [Ichihashi et al., 2003; Ziegler et al., 1994]. Other sources state that more than 50% of all 
BCC and 90% of all SCC harbour p53 mutations [Brash et al., 1996]. Usually, p53, also called the 
“guardian of the genome”, is associated with the induction of apoptosis, cell-cycle arrest or 
senescence following stress signals like DNA damage after UV exposure [Vousden and Lane, 2007]. 
Irreparable DNA damage leads to a p53-dependent induction of apoptosis pathways, thus eliminating 
damaged cells that could otherwise acquire a tumourigenic phenotype [Zuckerman et al., 2009]. In 
this event the pro-apoptotic protein Bak is activated, after induction by UVB, which was also 
reported to happen independently of p53 [Jackson et al., 2000]. Bak can multimerise in the 
mitochondrial membrane, release cytochrome c and thereby activate the pro-apoptotic caspase 
cascade [Underbrink et al., 2008]. In contrast to genital HPVs, cutaneous HPV types were not shown 
to bind p53 but to indirectly influence different pathways controlled by p53. For instance, viral E6 
protein binds HIPK2, prevents both HIPK2/p53 interaction and p53 phosphorylation at Ser46, 
resulting in the inhibition of apoptosis [Muschik et al., 2011]. 
In addition to the UV-mediated mutation of the p53 protein, a role for cutaneous HPVs as 
co-factors in this multi-step process of skin carcinogenesis has been suggested in epidemiological 
studies [Bouwes Bavinck et al., 2010; Feltkamp et al., 2003; Nindl et al., 2007; Pfister, 2003]. These 
studies uncovered an association between the presence of distinct HPV types and SCC but not BCC 
[Karagas et al., 2006; Stockfleth et al., 2004]. Yet, typically only small amounts of viral DNA are 
detectable in SCC and the exact mechanism of HPV-associated skin cancer development remains 
unclear. Cutaneous SCC represents the main type of tumour in immunosuppressed individuals e.g. 
organ transplant recipients (OTR), again underlining the important connection between the immune 
status and epithelial cancer. Organ transplant recipients have an increased risk to develop warts and 
NMSC, considering that up to 40% of renal transplant recipients and 90% of all OTR develop skin 
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cancer within 15 years after transplantation [Birkeland et al., 1995; Nindl et al., 2007; Nindl and Rösl, 
2008]. For these patients photoimmunosuppression is a matter of particular importance [Euvrard et 
al., 2003; Stockfleth et al., 2001]. Notably, there is a 100- to 250-fold increased incidence of SCC in 
OTR compared to the general population underlining the important connection between the immune 
status and this malignancy. In contrast, the incidence of BCC is only increased by a factor of 10 
[Euvrard et al., 2003; Hartevelt et al., 1990; Lindelof et al., 2000]. DNA from cutaneous HPV types 
was detected in over 80% of SCC from OTR compared to 36% in immunocompetent individuals, 
strongly suggesting a role for cutaneous HPVs in SCC pathogenesis. Also, the percentage of 
HPV-positive tumours was shown to increase with the number of observed lesions [Arends et al., 
1997; Harwood et al., 2000; Stockfleth et al., 2004]. Because of constant immunosuppression, 
infections with usually harmless cutaneous HPVs might not be cleared in OTR and could therefore 
contribute to uncontrolled cell proliferation of infected cells. Unlike in the case of genital high-risk 
HPVs, no direct connection between specific cutaneous HPV types and SCC has been established, yet. 
However, several studies support a role for beta2 HPVs in the development of SCC even in 
immunocompetent individuals, as an overall high prevalence of HPV DNA was observed among the 
general population  [Asgari et al., 2008; Karagas et al., 2006]. Contrary to high-risk genital HPV 
proteins that directly act as carcinogens, it is widely believed that their cutaneous analogues might 
act indirectly (e.g., by means of a “hit-and-run” mechanism), since not all tumour contain HPV DNA 
[Pfister, 2003]. Although associations have been identified in epidemiological studies, the exact role 
of cutaneous HPV infection in the development of SCC still remains unclear.  
Because this thesis initially focused on the characterisation of the novel E6 proteins and 
identification of their interaction partners, the later identified interaction partner Ajuba, belonging to 
the LIM domain proteins, is introduced in the following chapters. 
 
1.4 LIM domain proteins 
About 25 years ago novel cysteine-rich protein motifs were described common to a group of 
homeodomain transcription factors. This group of proteins was named after the initials of those 
three homeodomain proteins in which it was first discovered: Lin11 (Caenorhabditis elegans), Isl-1 
(rat) and Mec-3 (C. elegans), forming the acronym LIM [Freyd et al., 1990; Karlsson et al., 1990; Way 
and Chalfie, 1988]. The LIM domain can be found in proteins from ascidians, yeast, plants and 
humans and is highly conserved. The consensus sequence itself is variable between different species. 
Thereafter, several LIM homeodomain genes were isolated that contained two consecutive LIM 
domains combined with a conserved homeodomain. Additional genes were identified encoding 
LIM-domain proteins found in the cytoplasm as well as the nucleus. Some of the nuclear proteins 
mostly contain two LIM domains, and are therefore called LIM only proteins [Bach, 2000]. Individual 
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LIM domains consist of approximately 55 amino acids with 8 highly conserved residues (Fig. 1.3A). 
Initially, it was thought that the highly conserved residues might form a metal-binding structure 
containing iron-sulphur clusters [Li et al., 1991], however other studies showed that the LIM domain 
binds zinc and not iron [Michelsen et al., 1993]. The LIM domain arranges two zinc ions via two 
tetrahedral metal-coordinating centres formed by conserved cysteine, histidine, or aspartic acid 
residues of the consensus, thus forming a tandem zinc-finger (Fig 1.3B). This zinc coordination is 
necessary to stabilise the secondary and tertiary structures of the LIM domain [Kosa et al., 1994; 
Michelsen et al., 1994]. Furthermore, the two-residue linker between both zinc-finger modules 
seems to be indispensable for proper LIM domain function [Schmeichel and Beckerle, 1997]. In the 
beginnings of LIM domain research, it has been unclear whether the LIM domain was involved in 
protein-protein or protein-nucleic acid interactions. Although structural studies have shown that the 
domain has a tertiary fold indicative of a DNA-binding function, no evidence for a protein-DNA 
interaction has been presented to date [Perez-Alvarado et al., 1994]. 
 
Figure 1.3: Conserved sequence topology of the LIM domain. 
(A) The spacing of the eight zinc-binding residues (1-8) is based on analysis of 135 human LIM sequences. 
Occasionally observed patterns (seen in <10% of cases) are represented in characters that are not bold. Here, X 
denotes any amino acid. (B) Topology of the zinc coordination. Blue circles represent the zinc-binding residues. 
Semi-conserved aliphatic residues are shown in green. Non-conserved residues with invariant spacing are 
represented as bordeaux spheres. Dashed beige circles represent a variable number of residues (X) within the 
sequence. Figure adapted from Kadrmas and Beckerle [2004]. 
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LIM-domain proteins are diverse and the domain itself can be found in many eukaryotic 
organisms. However, LIM-domain proteins have not been found in prokaryotes [Kadrmas and 
Beckerle, 2004]. Currently, 135 LIM-encoding sequences are found in the human genome located 
within 58 genes. Human LIM-domain proteins can contain up to 5 LIM domains. The proteins 
themselves can consist of LIM domains only or the LIM domains can be combined with other 
domains like catalytic domains, homeodomains or other protein-protein binding modules including 
SH3 or PDZ domains. LIM domains can be located N- or C-terminally, but also internally in a protein. 
These characteristics demonstrate the functional diversity of LIM-domain proteins [Zheng and Zhao, 
2007]. 
LIM proteins can be located in the cytoplasm as well as the nucleus, but many LIM proteins, 
like the LIM homeodomain proteins, are found in the nucleus only. However, many LIM-domain 
proteins that were originally identified as cytoskeleton-associated proteins have been shown to 
shuttle between the nucleus and the cytoplasm thereby influencing gene expression [Chang et al., 
2003; Muller et al., 2002; Petit et al., 2000]. LIM domains were first classified into three groups based 
on sequence similarity, arrangement of the LIM domain and the overall structure [Dawid et al., 
1998]. Due to an increasing number of LIM-domain proteins, they were then classified into four 
groups. The first group contains LIM-homeodomain (LHX) proteins as well as nuclear LIM domain 
only (LMO) proteins, which have two repeated N-terminal LIM domains. These proteins are located 
in the nucleus and function as transcription factors. The second group contains LMOs which are 
located in the nucleus and the cytoplasm. They also contain several LIM domains located at the N- or 
C-terminus. Apart from the LIM domains, the third and fourth groups harbour other protein-protein 
interaction domains like leucine-aspartate repeats (LD) or PDZ domains. Additionally, proteins in the 
fourth group are catalytic, thereby differentiating them from the third group (Fig. 1.4). A similar 
categorisation of the four groups is: nuclear LIM proteins, LIM only proteins, actin associated LIM 
proteins, and catalytic LIM proteins referring to groups one to four, respectively [Kadrmas and 
Beckerle, 2004; Zheng and Zhao, 2007]. The protein further studied in this thesis is termed Ajuba and 
according to this classification belongs to the third group of LIM proteins. 
 The actin associated LIM-domain proteins e.g. members of the Enigma, Paxillin, and 
Ajuba/Zyxin protein families can shuttle between the nuclear and cytoplasmic compartments of the 
cell, thereby influencing gene expression [Breen et al., 1998]. Since they are very heterogeneous, 
proteins from this group are able to interact with a variety of partners. Some of these proteins can 
e.g. localise at sites of focal adhesions (Paxillin, Zyxin). Their translocation into the nucleus through 
extracellular signals leads to transcriptional regulation of target genes but can also allow them to 
function as co-repressors or -activators [Wang and Gilmore, 2003].  
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Structural analyses demonstrated that LIM domains are protein-binding interfaces mediating 
protein-protein interactions [Schmeichel and Beckerle, 1994]. So far, it is not clear whether the LIM 
domain has a specific consensus binding sequence. It has been shown that a single LIM domain is 
sufficient for the binding of a specific protein partner; however, the protein sequence neighbouring 
the LIM domain can amplify this binding. Furthermore, single LIM domains were identified to 
concurrently bind several proteins and other tandem LIM domains to synergistically bind a single 
partner [Deane et al., 2004; Sum et al., 2002].  
 
Figure 1.4: Classification and domain structure of LIM domain proteins. 
LIM domain proteins are classified into four groups according to the arrangement and position of their LIM 
domains. These groups are: Nuclear LIM proteins, LIM only proteins, Actin associated LIM proteins, and 
Catalytic LIM proteins.  Individual LIM domains are shown as purple boxes. All other domains are depicted as 
grey boxes and specified in the respective proteins. ActA, ActA repeat region; CH, calponin homology; G, 
glycine rich region; HD, homeodomain; PET, prickle, espinas and testin; LD, Leucine-aspartate domain; PDZ, 
Postsynaptic density-95, Discs large, Zona occludens-1; CRP, Cysteine-rich protein; FHL, Four-and-a-half LIM; 
PINCH, Particularly interesting new cysteine and histidine-rich protein; LIMK, LIM kinase; MICAL, Molecule 
interacting with CASL protein-1. Figure inspired by Zheng and Zhao [2007]. 
 
The LIM domain itself does not possess intrinsic catalytic activity, but LIM-domain proteins 
are known to induce a variety of biological processes via protein binding. Because LIM domains are 
protein-interaction platforms, it was suggested that they might modulate the activities of their 
binding partners [Schmeichel and Beckerle, 1994]. After analyses of many LIM interaction partners, 
four main LIM domain functions have been described: they can be adaptors, competitors, localisers, 
or autoinhibitors (Fig. 1.5). Whenever LIM-domain proteins contain additional protein-interaction 
domains they are able to function as adaptors or scaffolds and are thus capable of assembling a 
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multimeric protein complex. This brings the different protein partners into close proximity and can 
therefore have an impact on their activity (Fig. 1.5A). In addition, LIM domains can compete with 
each other for binding partners, thereby controlling biological activities (Fig. 1.5B) [Kadrmas and 
Beckerle, 2004]. Another mechanism for the control of protein activity is regulation through 
conformational changes (Fig. 1.5C). This autoinhibition process is common to a variety of 
transcription factors or members of the membrane-fusion machinery. Autoinhibition is an effective 
regulatory mechanism which works via inhibitory domains that negatively regulate functions of other 
domains through intramolecular associations [Pufall and Graves, 2002]. Lastly, LIM-domain proteins 
can affect subcellular protein localisation (Fig. 1.5D). They have been shown to participate in protein 
targeting by localising interaction partners in specific cellular compartments and by controlling their 
own localisation. Numerous transcription factors and kinases are regulated depending on their 
localisation [Cyert, 2001]. Often, combinations of the aforementioned functions can be observed in 
LIM-domain proteins. 
 
Figure 1.5: LIM domain functions. 
Functions of the LIM domain elicited through binding to protein partners. (A) Adaptors function as molecular 
scaffolds assembling interaction partners thereby promoting their activity. (B) The affinity of target proteins for 
different LIM domains may result in a competition effect, thus regulating the activity of the LIM complex. 
(C) Autoinhibition of LIM domains can occur through intramolecular associations. These interactions might 
produce a closed conformer whose activity differs from an open, or target-protein-occupied, conformer. 
(D) LIM-domain proteins can bring themselves and/or their binding partners to a particular cellular locus. 
Figure adapted from Kadrmas and Beckerle [2004]. 
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1.4.1 Ajuba/Zyxin family of LIM proteins 
The Ajuba/Zyxin protein families belong to the actin associated LIM proteins and contain 
altogether six members in the Ajuba subfamily (Ajuba itself, LIM domain-containing protein 1 
(LIMD1), and Wilms tumour 1 interacting protein (WTIP)) and the Zyxin subfamily (Zyxin, Lipoma 
preferred partner (LPP) and Thyroid hormone interacting protein 6 (Trip6)) (Fig. 1.6) [Crawford and 
Beckerle, 1991; Goyal et al., 1999; Kiss et al., 1999; Petit et al., 1996; Wang and Gilmore, 2003; Yi and 
Beckerle, 1998]. All of these proteins contain three tandem-repeated homologous LIM domains at 
their C-terminus and a non-homologous proline-rich N-terminal PreLIM region (Fig. 1.6). Within the 
LIM region the six proteins share a high sequence homology [Schmeichel and Beckerle, 1997]. 
   In fibroblasts and epithelial cells Ajuba/Zyxin family proteins are parts of cell-cell junction 
adhesive complexes [Marie et al., 2003]. In fibroblasts they affect cell motility, whereas in epithelial 
cells they take part in the establishment and maintenance of cell-cell junctions [Marie et al., 2003; Yi 
et al., 2002]. Additionally, all members of the Ajuba/Zyxin family contain a nuclear export signal (NES) 
in their PreLIM domains, enabling shuttling to and from the nucleus (Fig. 1.6) [Nix and Beckerle, 
1997]. This characteristic feature makes them excellent candidates for being involved in signal 
transduction, where information needs to be transported from the cell surface into the nucleus. 
 
Figure 1.6: Schematic representation of the Ajuba/Zyxin family of LIM proteins. 
This subgroup of LIM proteins is characterised by a non-homologous N-terminal PreLIM region including the 
nuclear export signal (NES) and three homologous C-terminal LIM domains. Phylogenetically, this family can be 
separated into two subfamilies, one being the Ajuba subfamily containing Ajuba, LIMD1 and WTIP, the other 
subfamily being Zyxin consisting of Zyxin, LPP, and Trip6. 
 
Ajuba/Zyxin family members localise to sites of focal adhesion, associate with the actin 
cytoskeleton, and take part in cell motility [Crawford et al., 1992; Petit et al., 2000; Yi et al., 2002]. 
Each subfamily also has its own special functions. Zyxin family members bind α-actinin and thus 
contribute to actin filament assembly. When the Zyxin-α-actinin interaction is disturbed, Zyxin is 
displaced from its normal subcellular localisation. This mislocalisation leads to disturbed cell 
migration and spreading  [Drees et al., 1999]. Moreover, Zyxin family members, but not the Ajuba 
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members, localise to cell-cell junctions in mammalian cells where they may participate together with 
Ena/VASP family members in the development of intercellular adhesive complexes [Renfranz et al., 
2003; Vasioukhin et al., 2000]. Zyxin was the first protein of the family where a functional NES was 
detected, but the biological consequences of this nuclear translocation are still unknown. Ajuba, on 
the other hand, is known to affect growth control and cell differentiation upon accumulation in the 
nucleus. This accumulation is induced through the removal of the PreLIM domain of Ajuba, resulting 
in a protein with just the LIM domains and lacking the nuclear export sequence [Goyal et al., 1999; 
Kanungo et al., 2000]. Still, the exact mechanism of Ajuba recruitment to the different cellular 
compartments is not well understood. Both, Ajuba and Zyxin, have been implicated in cellular 
regulation during mitosis. Both of them interact with the LATS tumour suppressors and Ajuba 
additionally associates with the mitotic kinase Aurora A [Abe et al., 2006; Hirota et al., 2003]. 
A strong line of evidence proposes that the Ajuba/Zyxin family proteins do not bind DNA 
directly, but as they translocate into the nucleus they might have indirect effects on transcription. 
Both family proteins are able to bind transcription factors and other nuclear proteins. They also 
exhibit transactivation potential as detected in reporter assays [Petit et al., 2000; Wang and Gilmore, 
2003]. The Ajuba/Zyxin family of LIM proteins has also been implicated in the regulation of other 
signalling pathways. The PreLIM region contains consensus SH3 recognition sites and Ajuba and Zyxin 
have been shown to interact with SH3 domains of Grb2 (Growth factor receptor-bound protein 2) 
and Vav, a proto-oncoprotein, respectively [Goyal et al., 1999; Hobert et al., 1996]. The interaction of 
Ajuba with Grb2 leads to increased MAP kinase activity in fibroblasts. Upon expression of murine 
Ajuba in Xenopus oocytes, meiotic maturation takes place in a Grb2- and Ras-dependent manner. 
The functional significance of the interaction of Zyxin with Vav is however unclear [Goyal et al., 
1999]. Taken together, the Ajuba/Zyxin families play an important role in signal transduction, 
whereas the individual proteins might have overlapping roles. However, there is evidence that the 
roles of both subfamilies, Ajuba and Zyxin, diverge in the epithelial system. 
 
1.4.2 Functions and cellular roles of the Ajuba family of LIM proteins 
To further understand the role of Ajuba LIM proteins in signal transduction, interaction 
assays were performed and a new binding partner, the atypical protein kinase C (aPKC) scaffold 
protein p62, was identified. A well-known function of p62 is the regulation of NF-κB activation after 
interleukin-1 (IL-1) and tumour necrosis factor signalling by formation of an aPKC/p62/TRAF6 
signalling complex. Hence, it was proposed that Ajuba belongs to the IL-1 signalling pathway where it 
modulates the IL-1-induced NF-κB activation by impacting the assembly and activity of the 
aPKC/p62/TRAF6 multiprotein signalling complex [Feng and Longmore, 2005].  
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Inside the nucleus, Ajuba LIM proteins were found to interact with the SNAG domain of Snail, 
a transcriptional repressor. Ajuba family members are recruited to the endogenous E-cadherin 
promoter, thus contributing to Snail-dependent repression of E-cadherin. This suggests that these 
proteins are essential regulators facilitating the communication between the surface of the cell and 
the nuclear response [Langer et al., 2008]. Another study aiming at elucidating the function of Ajuba 
LIM proteins in the nucleus found that the protein arginine methyltransferase 5 (PRMT5) is recruited 
to Snail through the interaction with Ajuba, repressing the Snail target gene E-cadherin. There, 
PRMT5 binds to the PreLIM region and gets translocated into the nucleus in a Snail- and 
Ajuba-dependent manner. Therefore, PRMT5 is presented as a key component in the Snail-silencing 
complex through its interaction with Ajuba [Hou et al., 2008]. 
The Ajuba subfamily of LIM proteins is expressed in organs abundant in epithelia, such as 
skin, lung, liver or kidney. It was shown that upon formation of cell layers, Ajuba was localised to 
cell-cell contacts [Goyal et al., 1999; Kanungo et al., 2000]. In primary human keratinocytes Ajuba 
was shown to co-localise with the cadherin adhesive complex at sites of cell-cell contacts, like 
cell-cell junctions. This localisation of Ajuba is in contrast to Zyxin localisation which is predominantly 
found at focal adhesion sites, again underlining that both families, the Ajuba and the Zyxin family, 
might have divergent functions. It was demonstrated that Ajuba is recruited to membrane cadherin 
adhesive complexes at adherens junctions after binding to α-catenin. In addition to α-catenin, 
another interaction partner of Ajuba, F-actin, was found interacting with the PreLIM region of Ajuba 
[Marie et al., 2003]. Ajuba null mice are viable and appear healthy and fertile. However, primary skin 
keratinocytes isolated from these mice display abnormal cell-cell adhesion and defects in skin wound 
healing [Feng and Longmore, 2005]. The LIM domains target Ajuba to epithelial junctions through a 
regulated interaction with α-catenin [Kanungo et al., 2000; Reinhard et al., 1999], while the PreLIM 
domain of Ajuba directs its interaction with filamentous actin [Marie et al., 2003]. The 
aforementioned data suggest that Ajuba may contribute to the bridging of cadherin adhesive 
complexes to the actin cytoskeleton through its interaction with α-catenin and F-actin. Therefore it 
may play a role in the formation or strengthening of adherens junctions [Marie et al., 2003]. 
Although the exact mechanisms for these processes are not completely known and 
understood, the already obtained data give hints to the different roles of the Ajuba LIM proteins in 
the context of cellular processes. Based on the ability of Ajuba LIM proteins to shuttle between 
nucleus and cytoplasm there is a strong indication for them being involved in signal transduction 
between cell-cell junctions, cytoplasm and nucleus. One important complication in uncovering 
specific physiological roles is the possibility of functional redundancy between the Ajuba LIM family 
proteins Ajuba, LIMD1, and WTIP, which makes it difficult to analyse the distinct functions of the 
individual proteins.  
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1.5 Objective of the thesis 
While it is proven that infections with high-risk HPV types cause cervical cancer, the role of 
cutaneous HPV types in the development of certain skin cancers is not fully understood. Thus, the 
oncogenic potential of the majority of cutaneous HPV types remains unclear, partly because of the 
high number of cutaneous types. 
Previous studies identified several novel HPV types belonging to the genera alpha2 
(HPV117), beta1 (HPV118), gamma7 (HPV134), and gamma11 (HPV148). Additionally, a yeast 
two-hybrid screening was performed on HPV4 E6 identifying five interaction candidates. To combine 
these results, the aim of this PhD thesis was to identify new interaction partners for the known and 
novel HPV types. Furthermore, the underlying mechanism of the successfully identified interaction of 
Ajuba with cutaneous HPV E6 proteins was studied, also upon UV-induced DNA damage. The major 
aims of this study therefore were: 
 
(1) to verify the identified potential interaction partners for HPV4 E6 with respect to the 
novel HPV types; 
 
(2) to map the protein binding region of E6 with Ajuba, once Ajuba was identified as the 
most promising binding partner; 
 
(3) to analyse Ajuba’s role in HPV E6 protein accumulation and DNA damage response; 
 
(4) to examine the role of the p53 protein with HPV E6 and Ajuba. 
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S e c t i o n 2 
 
Results 
 
2.1 Cutaneous HPV E6 proteins from the beta2, gamma1, and gamma11 
genera interact with Ajuba 
In order to identify new interaction partners for known and novel HPV types, a yeast 
two-hybrid screening was performed with the E6 protein of HPV4, a well-known HPV type from the 
gamma genus [Heilman et al., 1980]. This task was processed by the South Korean company 
PanBioNet prior to the start of this thesis. The company identified five putative HPV4 E6 interacting 
candidates: Programmed cell death 6-interacting protein (PDCD6IP, Alix), an uncharacterised protein 
named Chromosome 9 open reading frame 102 (C9orf102), Ajuba, Leupaxin and Plectin (Fig. 2.1). 
The binding of these five potential interaction proteins to HPV4 E6 had to be confirmed, but first it 
was assessed whether it was possible to analyse all of them. Of the five above mentioned proteins, 
Plectin was standing out in particular because of its size. Being larger than 500 kDa, it excluded from 
the study, because it was considered unfeasible to deal with this protein at full length. Hence, it was 
decided to first work with the remaining proteins, which could be handled as full-length constructs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic illustration of the workflow of the identification of binding partners of novel HPV 
types. 
Prior to the project start a Yeast Two-Hybrid (Y2H) screening with HPV4 E6 was performed, identifying five 
putative interaction partners. These were Programmed cell death 6-interacting protein (PDCD6IP), the 
uncharacterised protein Chromosome 9 open reading frame 102 (C9orf102), Ajuba, Leupaxin, and Plectin. After 
initial experiments (see section 2.1.1) only Ajuba displayed in vitro and in vivo binding.  
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2.1.1 Identification of Ajuba and C9orf102 as promising candidates for                                                     
interaction with HPV E6 proteins 
In order to study the presence of a direct interaction of HPV E6 proteins with PDCD6IP, 
Leupaxin, C9orf102 or Ajuba, glutathione S-transferase (GST) pull-down experiments (see section 
5.3.3) were performed (Fig. 2.2). The full-length forms of the above mentioned proteins were 
35S-radioactively labelled by in vitro translation (see section 5.3.1) and their binding to purified 
GST-tagged E6 fusion proteins of various HPV types was tested. Purified GST protein was used as a 
negative control to exclude the possibility of unspecific binding to the N-terminal GST-tag of the 
fusion proteins. To visualise proteins loaded on the gel and to assess the protein concentration used 
for the GST pull-down experiments, Coomassie staining of the SDS-PAGE gel was performed. 
Additionally, 10% of total 35S-radioactively labelled in vitro translated proteins were applied to the 
SDS-PAGE gels as input, to estimate binding intensity. Figure 2.2A depicts the GST pull-down of 
PDCD6IP. There, no interactions were observed with either of the E6 proteins of the novel HPV types, 
belonging to the genera alpha2 (HPV117), beta1 (HPV118), gamma7 (HPV134), gamma11 (HPV148), 
nor with HPV4 E6 (gamma1), used as a Y2H positive control. PDCD6 (Programmed cell death protein 
6) was included as an accurate positive control, which indeed was found to interact with PDCD6IP. 
Hence, the method itself worked under the chosen conditions, but distinct interactions with the E6 
proteins could not be detected. Due to the lack of in vitro interaction with the novel HPV E6 proteins, 
PDCD6IP was excluded from further studies. Figure 2.2B shows the GST pull-down of Leupaxin (LPXN) 
with the E6 proteins of the novel HPV types as well as HPV4 E6 and HPV16 E6. Here, very weak 
interactions were observed between Leupaxin and HPV16 E6 or HPV148 E6. Both bands were 
however much weaker than the 10% input signal and were thus not considered as definite in vitro 
interactions. As another putative interaction partner C9orf102 was analysed (Fig. 2.2C). Here, 
GST-HPV4 E6 and GST-HPV148 E6, both belonging to the gamma genus, were found to strongly 
interact with the full-length protein of C9orf102 in vitro. Therefore, it was decided to test whether 
the in vitro interaction of C9orf102 with HPV148 E6 could also be verified in vivo (Fig. 2.3). Finally, the 
interaction of Ajuba with different HPV E6 proteins was assessed. Figure 2.2D depicts a strong 
interaction between full-length Ajuba protein and GST-HPV23 E6 as well as GST-HPV148 E6. 
Additionally, weak interactions with GST-HPV16 E6 and GST-HPV118 E6 were observed. On the 
contrary, GST-tagged E6 fusion proteins of HPV4, HPV117, and HPV134 failed to interact with Ajuba 
in vitro in this experimental setting.  
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Figure 2.2: GST pull-down of novel HPV E6 proteins with the putative interaction partners of HPV4 E6. 
GST-tagged E6 fusion proteins of diverse HPV types, GST or a positive control were incubated with in vitro 
translated 
35
S-radioactively labelled (A) PDCD6IP, (B) Leupaxin (LPXN), (C) C9orf102 or (D) Ajuba. Uncoupled 
GST was used as a negative control. GST pull-down experiments were analysed by SDS-PAGE and Coomassie 
staining (lower panels). The gels were dried and exposed to X-ray films (Autoradiograms, upper panels). 10% of 
the respective total 
35
S-radioactively labelled proteins were used as input. 
 
2.1.2 C9orf102 does not interact with HPV148 E6 in vivo 
In order to assess whether the identified protein interaction of C9orf102 with the HPV E6 
proteins (Fig. 2.2C) also occurred in vivo, co-immunoprecipitation (Co-IP) analyses were performed 
using HA-tagged HPV148 E6 protein. Therefore, HEK293 cells were used because of their 
characteristic of being HPV-negative, easy to transfect and their ability to produce large amounts of 
proteins. Hence, HA-tagged HPV148 E6 and Flag-tagged C9orf102 proteins were expressed in HEK293 
cells and complex formation was determined by Co-IP analyses (see section 5.4) using target 
protein-specific antibodies. As an input control, 30% of whole cell lysates were analysed for protein 
expression by Western blotting. To eliminate the possibility of unspecific protein binding, Co-IPs were 
additionally performed in the absence of antibody-specific target proteins. Co-IP analyses using both 
anti-HA and anti-Flag antibodies showed that Flag-C9orf102 and HPV148 E6-HA proteins were not 
able to form a complex in vivo (Fig. 2.3). Therefore the potential interaction partner protein C9orf102 
was excluded from further experiments as it failed to interact with HPV148 E6 in vivo, an essential 
criterion, as not every in vitro interaction can also be verified in vivo.  
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Figure 2.3: C9orf102 protein does not co-precipitate with HPV148 E6 in vivo. 
HEK293 cells were transfected with HA-tagged HPV148 E6 and/or Flag-C9orf102 and immunoprecipitated with 
(A) Flag (IP: Flag) or (B) HA (IP: HA) antibodies. Complexes were analysed by Western blotting (IP, upper panel). 
As an input control, 30% of cell lysates were analysed for protein expression (Input: 30%, lower panel). The 
heavy chain of the precipitating antibody (IgGH) is indicated. 
 
2.1.3 Ajuba interacts with cutaneous HPV E6 proteins from the beta2, gamma1 and 
gamma11 genera in vivo 
In order to evaluate whether the in vitro interaction of Ajuba with the HPV E6 proteins did 
also occur in vivo, Co-IP experiments were performed. Therefore, HA-tagged HPV4 E6, HPV23 E6, 
HPV148 E6 (Fig. 2.4A-C), HPV16 E6, HPV117 E6 proteins (Fig. 2.5A and B) and Flag-Ajuba were 
expressed in HEK293 cells and complex formation was investigated by Co-IP analyses. As input 
control, 15% of whole cell lysates were analysed for protein expression by Western blotting. To 
exclude unspecific protein binding, controls IPs in the absence of antibody-specific target proteins 
were performed. Co-IP analyses using an anti-Flag antibody revealed that Flag-Ajuba and 
HPV4 E6-HA, HPV23 E6-HA and HPV148 E6-HA proteins were indeed able to form a complex in vivo 
(Fig. 2.4). On the contrary, the HA-tagged HPV16 E6 protein, which was shown to weakly bind Ajuba 
in vitro (Fig. 2.2D), failed to co-precipitate with Flag-Ajuba in vivo. The same occurred for 
HPV117 E6-HA, except that for this protein it had already not been possible to show in vitro binding, 
which made it an additional negative control. 
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Figure 2.4: Ajuba protein co-precipitates with HPV4 E6, HPV23 E6 and HPV148 E6 in vivo. 
HEK293 cells were transfected with HA-tagged HPV4 E6 (A), HPV23 E6 (B) or HPV148 E6 (C) and/or Flag-Ajuba 
and immunoprecipitated with Flag antibody (IP: Flag). Complexes were analysed by Western blotting (IP, upper 
panels). As an input control, 15% of cell lysates were analysed for protein expression (Input: 15%, lower 
panels). The heavy chain of the precipitating antibody (IgGH) is indicated. 
 
 
Figure 2.5: Ajuba protein does not co-precipitate with HPV16 E6 and HPV117 E6 in vivo. 
HEK293 cells were transfected with HA-tagged HPV16 E6 (A) or HPV117 E6 (B) and/or Flag-Ajuba and 
immunoprecipitated with Flag antibody (Flag: IP). Complexes were analysed by Western blotting (IP, upper 
panels). As an input control, 15% of cell lysates were analysed for protein expression (Input: 15%, lower 
panels). The heavy chain of the precipitating antibody (IgGH) is indicated. 
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2.1.4 Ajuba interacts with HPV4 E6, HPV23 E6, and HPV148 E6 through its PreLIM 
domain 
In order to map the binding region required for HPV E6 protein interaction in more detail 
(Fig. 2.2D), two smaller deletion constructs, the PreLIM and LIM domains of Ajuba (Fig. 2.6), were 
employed to analyse GST-HPV E6 protein binding. Figure 2.6 shows a schematic overview of the 
Ajuba full-length protein and both deletion constructs which were analysed for direct interaction to 
GST-tagged HPV E6 proteins. The N-terminal part of Ajuba, comprising its PreLIM region, was found 
to strongly interact with HPV23 E6 and HPV148 E6, but also with HPV4 E6 and slightly with 
HPV118 E6 (Fig. 2.7A). By contrast, deletion of the N-terminus, leaving the LIM region of Ajuba, 
abolished the binding to the above mentioned HPV E6 proteins, but showed binding of HPV16 E6 to 
the LIM domain (Fig. 2.7B).  
 
Figure 2.6: A schematic overview of the in vitro transcribed and translated Ajuba constructs analysed in GST 
pull-down experiments. 
The Ajuba full-length protein can be separated into two main domains, the N-terminal PreLIM region and the 
C-terminal LIM region. The PreLIM region is a non-homologous domain rich in proline and contains a nuclear 
export signal (NES). The LIM region consists of three homologous C-terminal LIM domains. 
 
 
Figure 2.7: HPV4 E6, HPV23 E6 and HPV148 E6 interact with Ajuba via its PreLIM domain in vitro. 
GST-tagged E6 fusion proteins of various HPV types or GST alone were incubated with in vitro translated 
35
S-radioactively labelled (A) Ajuba’s N-terminal PreLIM domain (PreLIM) or (B) Ajuba’s C-terminal LIM domain 
(LIM). GST was used as negative control. GST pull-down experiments were analysed by SDS-PAGE and 
Coomassie staining (lower panels). Gels were dried and exposed to X-ray films (Autoradiograms, upper panels). 
10% of total 
35
S-radioactively labelled Ajuba was used as input. 
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2.2 HPV4-, HPV23-, and HPV148 E6 proteins co-localise with Ajuba in the 
cytoplasm 
The preceding experiments depicted in vitro and in vivo interactions of cutaneous HPV E6 
proteins from the beta and gamma genera with Ajuba. In order to determine whether the interaction 
was significant for the cellular localisation of the HPV E6 proteins and Ajuba, immunofluorescence 
analyses were performed (see section 5.5.7). For this and further parts of the study, U2OS cells were 
used due to their characteristic of undergoing apoptosis following genotoxic stress [Allan and Fried, 
1999]. First, the cellular localisation of HA-tagged HPV4 E6, HPV16 E6, HPV23 E6 and HPV148 E6 
proteins as well as Ajuba was investigated using immunofluorescence microscopy. Therefore, U2OS 
cells were transfected with expression plasmids encoding HA-tagged HPV E6 proteins or Flag-tagged 
Ajuba protein. 48h later, cells were fixed and stained with either anti-HA or anti-Flag antibodies. 
Immunofluorescence microscopy exposed a diffuse cytoplasmic localisation pattern of HA-tagged 
HPV4 E6 and HPV16 E6 proteins. HPV23 E6 and HPV148 E6 proteins, on the other hand, showed a 
strong nuclear localisation with a diffuse expression pattern in the nucleus as well as in the 
cytoplasm (Fig. 2.8A). When expressed alone, Flag-tagged Ajuba revealed a scattered, predominantly 
cytoplasmic localisation (Fig. 2.8B; Fig. 2.9, upper panel), which was consistent with previous studies 
[Hou et al., 2008].  
In order to examine the cellular localisation of Ajuba in the presence of the various HPV E6 
proteins via immunofluorescence analyses, U2OS cells were transfected with expression plasmids for 
both Flag-Ajuba and HA-tagged HPV4 E6, HPV16 E6, HPV23 E6 and HPV148 E6 or the empty vector 
control pPK-CMV-E3 (Fig. 2.9).  
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Figure 2.8: HPVE6 proteins are localised throughout the cell in a diffuse pattern. 
U2OS cells were transiently transfected with (A) HA-tagged HPV4 E6, HPV16 E6, HPV23 E6 or HPV148 E6 or 
with (B) Flag-tagged Ajuba expression plasmids and then detected by immunofluorescence microscopy. 
Nuclear DNA (blue) was stained with Hoechst. The localisation of the E6 proteins is shown in red, Ajuba is 
represented in green. The scale bar represents 10µm. 
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Figure 2.9: Ajuba co-localises with HPV4 E6, HPV23 E6 and HPV148 E6 in the cytoplasm. 
U2OS cells were transiently transfected with the empty control vector pPK-CMV-E3, HA-tagged HPV4 E6, 
HPV16 E6, HPV23 E6 or HPV148 E6 in combination with Flag-Ajuba and then detected by immunofluorescence 
microscopy. Co-localisation of HPV E6-HA proteins (red) and Flag-Ajuba (green) is represented on merged 
images (yellow). Nuclear DNA (blue) was stained with Hoechst. The scale bar represents 10µm. 
 
Upon co-expression of individual E6 proteins and Ajuba, the distribution of each protein was 
not significantly changed. However, co-localisation could be observed in case of Ajuba and HPV4 E6, 
HPV23 E6 and HPV148 E6 (Fig. 2.9) in distinct areas in the cytoplasm, confirming the interaction 
observed in the Co-IP experiments (Fig. 2.4). To ensure that the visualised co-localisation was 
dependent on the interaction of Ajuba with the above mentioned HA-tagged HPV E6 proteins, the 
cellular localisation of HPV16 E6, which was previously shown not to bind Ajuba in vivo (Fig. 2.5A), 
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was also analysed in the presence of Flag-tagged Ajuba. The prevalent cytoplasmic Ajuba staining did 
not co-localise with the diffuse HPV16 E6 staining (Fig. 2.9), demonstrating that Ajuba indeed 
co-localises specifically with the E6 proteins of HPV4, HPV23 and HPV148. 
 
2.3 Ajuba’s role in HPV E6 protein accumulation and DNA damage 
response  
 
2.3.1 HPV23 E6 and HPV148 E6 proteins accumulate upon Ajuba overexpression 
To gain insight into the general endogenous distribution of the Ajuba protein, different 
human epithelial cell lines were analysed for its expression by Western blotting. Interestingly, the 
highest expression levels were found in HPV16 E6, -E7, and -E6/E7-positive keratinocytes as well as in 
the metastatic HPV16-positive cervical carcinoma cell line CaSki. Medium expression levels were 
detected in the HPV-negative cell line C-33 A, the non-small cell lung carcinoma cell line H1299 and 
the osteosarcoma cell line U2OS. Background protein levels were present in the neonatal human 
primary keratinocytes (HPKn), the near-diploid keratinocyte cell line NIKS [Allen-Hoffmann et al., 
2000], the HPV16-positive carcinoma cell line SiHa and HPV18-positive HeLa cells and the malignant 
melanoma cell line SK-MEL-28 (Fig. 2.10).  
All these cell lines were tested to determine whether Ajuba protein levels in general differ 
between HPV-positive and HPV-negative cell lines. As the result was not definite, it was tested 
whether overexpression of HPV E6 proteins or Ajuba have effects on the respective other protein.  
 
 
Figure 2.10: Expression of endogenous Ajuba varies in different human cell lines. 
Endogenous protein levels of Ajuba were analysed by Western blotting in various cell lines. These were 
neonatal Human Primary Keratinocytes (HPKn), HPV16 E6, -E7, or -E6/E7 -positive primary keratinocytes, the 
HPV-negative cell line C-33 A, a spontaneously immortalised near-diploid keratinocyte cell line (NIKS), HPV16-
positive CaSki and SiHa cells, and HPV18-positive HeLa cells, a non-small cell lung carcinoma cell line (H1299), 
an osteosarcoma cell line (U2OS) and the melanoma cell line (SK-MEL-28). Equal protein loading was monitored 
by using actin as control. 
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All these cell lines were tested to determine whether Ajuba protein levels in general differ 
between HPV-positive and HPV-negative cell lines. As the result was not definite, it was tested 
whether overexpression of HPV E6 proteins or Ajuba have effects on the respective other protein. 
Therefore, the HPV-negative p53-null cell line H1299 [Radhakrishna Pillai et al., 2004] was chosen for 
Western blot analyses to examine this relation of Ajuba and the E6 proteins of HPV23 and HPV148, 
omitting a potential influence of the p53 protein. As previous study demonstrated that cutaneous 
HPV23 E6 accumulated upon DNA damage [Muschik et al., 2011], it was decided to analyse whether 
this effect could also be observed in the chosen model system. Additionally, the osteosarcoma cell 
line U2OS was used due to its wild type p53 status, to analyse the effects of the interaction of Ajuba 
with HPV E6 proteins on the p53 status. Further analysis of HPV4 E6 in the context of Ajuba 
expression levels was adjourned and the focus was put on the novel HPV148 E6 protein and the 
already well characterised HPV23 E6 protein [Muschik et al., 2011]. 
In order to evaluate whether the interaction of Ajuba with HPV23 E6 and HPV148 E6 affected 
E6 protein accumulation, co-transfection experiments were performed. Therefore, HA-tagged 
HPV23 E6 and HPV148 E6 as well as Flag-Ajuba were expressed in H1299 cells. Protein levels were 
assessed by Western blotting. Intriguingly, a concomitant increase in Flag-Ajuba protein levels was 
observed upon increasing expression of HPV23 E6-HA and HPV148 E6-HA (Fig. 2.11A and B). 
Moreover, Flag-Ajuba overexpression exhibited the same effect on HPV148 E6-HA protein levels 
(Fig. 2.11C), demonstrating that the accumulation of at least HPV148 E6 was reversible. Additionally, 
a GFP expression plasmid, harbouring the same promoter as the HPV E6 expression constructs, was 
used together with Flag-Ajuba to prove that the increase in protein levels was due to the interaction 
itself and not because of increased promoter availability (Fig. 2.11D). 
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Figure 2.11: Increased expression of HPV23 E6 and HPV148 E6 leads to an accumulation of Ajuba. 
H1299 cells were transiently transfected with HA-tagged HPV23 E6 (A), HPV148 E6 (B, C), GFP (D) and/or 
Flag-Ajuba. Protein levels were analysed by Western blotting. Actin was used to assess equal loading. 
 
 
To confirm that Ajuba is essential for the accumulation of HPV23 E6 and HPV148 E6 proteins, 
endogenous Ajuba was down-regulated using siRNA in stably transfected H1299 and U2OS cells. 
Protein expression of Ajuba and the E6 proteins was determined by Western blot analyses (see 
section 5.2.5). Indeed, a reduction in HPV23 E6 and HPV148 E6 protein levels was observed in Ajuba 
knockdown cells which was more substantial in H1299 cells (Fig. 2.12A) than in U2OS cells (Fig. 
2.12B), corroborating a direct role for Ajuba in HPV E6 protein accumulation. Furthermore, p53 
protein levels were reduced in Ajuba knockdown cells (Fig. 2.12B), indicating a role for the p53 
protein when expressed together with Ajuba and HPV E6 proteins. On the contrary, treatment with 
scramble control siRNA (siScr) did not affect Ajuba or HPV E6 protein levels (Fig. 2.12). 
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Figure 2.12: Down regulation of Ajuba by siRNA affects HPV23 E6 and HPV148 E6 protein levels. 
Stably transfected (A) H1299 or (B) U2OS cells, expressing HA-tagged HPV23 E6 or HPV148 E6, were 
transfected with control siRNA (siScr) or with siRNA against Ajuba (siAjuba) for specific Ajuba down-regulation. 
Ajuba knockdown efficiency and E6 protein levels were determined by Western blotting. pPK-CMV-E3 (pPK) 
was used as empty vector control. Actin was used to assess equal loading. 
 
2.3.2 HPV23 E6 and HPV148 E6 protein levels decrease upon DNA damage 
Previous studies reported that LIM domain proteins might be involved in the repression of 
the DNA damage response at telomeres [Sheppard et al., 2011]. Ajuba in particular was described to 
repress the ATR-mediated DNA damage response [Kalan et al., 2013]. To analyse this hypothesis in 
the context of this study here, p53 wild type U2OS cells were used for Western blot analyses to study 
the effect of UVB- or chemotherapeutically induced DNA damage on HPV E6 proteins (see section 
5.5.6). Therefore, U2OS cells stably expressing HA-tagged HPV23 E6 or HPV148 E6 were treated with 
different dosages of UVB (0, 300, or 1,000 J/m2) or incubated with medium supplemented with 
Adriamycin (ADR), an agent intercalating with DNA and RNA [Momparler et al., 1976] (Fig. 2.13). 
Remarkably, DNA damage generated by either UVB irradiation or ADR treatment resulted in the 
degradation of endogenous Ajuba and in a coinciding decrease in HPV E6 protein (Fig. 2.13A and B). 
Protein levels of p53 increased upon rising irradiation doses (Fig. 2.13A) and ADR incubation times 
(Fig. 2.13B). PARP protein expression and its cleavage were analysed to determine if the cells 
underwent apoptosis [Boulares et al., 1999]. Indeed, stably transfected U2OS cells expressing the 
HA-tagged HPV23- and HPV148 E6 proteins showed PARP cleavage upon the longest exposure to 
ADR (Fig. 2.13B). 
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Figure 2.13: DNA damage leads to a decrease in HPV23 E6 and HPV148 E6 protein levels. 
Stably transfected U2OS cells were treated with (A) different dosages of UVB (0, 300, 1,000 J/m
2
) for 24h or (B) 
Adriamycin (1µg/mL; ADR) and harvested at indicated time points. Protein levels were analysed by Western 
blotting. Actin was used to assess equal loading. 
 
2.4 HPV23 E6, HPV148 E6 and Ajuba proteins undergo a complex 
formation with the p53 protein  
The evident involvement of the p53 protein in the Ajuba and HPV E6 complex seen in the 
siRNA knockdown (Fig. 2.12) and the DNA damage experiments (Fig. 2.13) encouraged the question 
whether an additional, larger complex would be formed when all three proteins (Ajuba, p53 and 
HPV E6) come together. Therefore, HA-tagged HPV23 E6 (beta1) or HPV148 E6 (gamma11), YFP-p53 
and Flag-Ajuba were expressed in H1299 cells and complex formation was analysed in co-
immunoprecipitation assays (see section 5.4). As an input control, 10% or 15% of whole cell lysates 
were analysed for respective protein levels by Western blotting. As previously shown, (Fig. 2.4B and 
C) Flag-Ajuba could be efficiently co-precipitated with HPV23 E6-HA and HPV148 E6-HA (Fig. 2.14A 
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and B). When performing a Flag-IP, no interaction was observed between Flag-Ajuba and p53 (Fig. 
2.14A and B). Interestingly, a complex formation was detected between Ajuba, p53 and 
HPV148 E6-HA (Fig. 2.14B), but no interaction was seen for HPV23 E6-HA (Fig. 2.14A).  
Figure 2.14: p53 forms a complex with Ajuba and HPV148 E6. 
H1299 cells were transfected with YFP-p53 and Flag-Ajuba either alone or in combination with HA-tagged 
HPV23 E6 (A, C) or HPV148 E6 (B, D) and immunoprecipitated with Flag (IP: Flag) or GFP (IP: GFP) antibodies. 
Complexes were analysed by Western blotting (upper panels). As input control, 10% or 15% of respective cell 
lysates were analysed for protein levels (Input, lower panels). The heavy chains of the precipitating antibodies 
(IgGH) are indicated. 
 
To address this particular observation from another angle, the same experimental setup was 
used, but instead of a Flag-IP a GPF-IP was performed. A GFP-IP was chosen, because the GFP 
antibody can bind to the YFP part of YFP-p53 very efficiently, YFP being a point mutatant of GFP 
[Wachter et al., 1998]. Moreover, YFP-p53 was transfected in every reaction, whereas Flag-Ajuba was 
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not. Although the GFP-IP clearly worked, again no complex formation could be observed for 
HPV23 E6, Ajuba and p53 (Fig. 2.14C). On the other hand, HPV148 E6 showed a clear complex 
formation with Ajuba and p53. In addition, a novel interaction between p53 and HPV148 E6 could be 
visualised (Fig. 2.14D). Hence, the results demonstrate a strong complex formation between 
HPV148 E6-HA, Ajuba and p53 that was highly specific for HPV148 E6 and not for HPV23 E6. 
 
2.4.1 HPV148 E6 interacts with p53 in vitro and in vivo  
The co-immunoprecipitation of the HPV E6 proteins with Ajuba and p53 prompted the 
question, whether the p53 protein indeed binds to cutaneous HPV E6 proteins in vitro and/or in vivo. 
HPV16 E6 as well as HPV18 E6 proteins are known to bind to p53 [Lechner and Laimins, 1994; 
Werness et al., 1990], whereas cutaneous HPV E6 proteins are reported not to do so. To address 
whether HPV148 E6 is able to bind p53, first a GST pull-down was performed using full-length in vitro 
transcribed and translated p53 protein (see sections 5.3.1 and 5.3.3). Binding was tested with 
GST-tagged HPV23 E6 and HPV148 E6. GST-HPV16 E6 was used as a positive control and purified GST 
protein as a negative control to exclude unspecific binding.  
Surprisingly, not only HPV16 E6 was found to bind to the p53 protein in vitro, but also 
cutaneous E6 proteins from both HPV23 and HPV148 (Fig. 2.15A). These newly identified in vitro 
interactions were subsequently also assessed in vivo. Therefore separate Co-IP experiments (see 
section 5.4) were performed using HA-tagged HPV23 as well as HPV148 E6 proteins and the 
YFP-tagged p53 protein. As already observed in figure 2.14C, HPV23 E6 does not interact with p53 
in vivo (Fig. 2.15B), even when a 5% input was used, meaning that 95% of the reaction was employed 
in the immunoprecipitation. On the contrary, HPV148 E6 clearly bound to the p53 protein in vivo 
(Fig. 2.15C). Additionally, it was analysed whether the p53 protein was able to interact with 
Flag-tagged Ajuba. Also in this case, 5% of the whole reaction mixture was used as input and the 
residual 95% for the immunoprecipitation reaction. Clearly, Ajuba did not interact with the p53 
protein (Fig. 2.15D). 
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Figure 2.15: HPV148 E6 interacts with p53 in vitro and in vivo. 
(A) GST-tagged E6 fusion proteins of HPV16, -23, and -148 or GST were incubated with in vitro translated 
35
S-radioactively labelled p53. GST and HPV16 were used as negative and positive controls, respectively. GST 
pull-down experiments were analysed by SDS-PAGE and Coomassie staining (upper panel). The gel was dried 
and exposed to X-ray films (Autoradiogram, lower panels). 10% of total 
35
S-radioactively labelled p53 was used 
as input. (B, C, D) H1299 cells were transfected with YFP-p53 and/or HA-tagged HPV23 E6 (B), HPV148 E6 (C), 
or Flag-Ajuba (D) and immunoprecipitated with a GFP antibody (IP: GFP). Immunoprecipitated proteins were 
analysed by Western blotting (IP, upper panels). As an input control, 5% or 15% of cell lysates were analysed 
for protein expression (Input, lower panels).  
 
2.4.2 Mapping of the binding site of p53 with HPV148 E6 
Based on the finding that HPV148 E6 binds to p53 both in vitro and in vivo, it was decided to 
further map the interaction site in p53. Figure 2.16A shows a schematic representation of the p53 
protein with its distinct domains, while Figure 2.16B represents the p53 full-length protein and all 
deletion constructs which were analysed for direct interaction to GST-tagged HPV E6 proteins.    
Full-length Flag-p53 showed a distinct binding to HPV16 E6 and a strong binding to 
HPV148 E6 (Fig. 2.16C, left panel), comparable to figure 2.15A.  When only the amino acids 1-70 of 
p53 were expressed, comprising mainly the Transactivation domain, the binding to HPV148 E6 was 
completely abrogated, implying that this domain itself was not alone responsible for the interaction 
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with HPV148 E6. Upon deletion of the C-terminus (Flag-p53 1-298), binding efficiency to HPV148 E6 
was increased compared to the full-length p53 protein. When the Transactivation and Proline-rich 
domains were missing (Flag-p53 80-393), binding of the p53 construct to HPV148 E6 was reduced, 
but still present. At last, the presence of the C-terminus only, namely the Tetramerization (Tet) and 
the C-terminal domains (Flag-p53 294-393), resulted in weak binding to HPV148 E6, but background 
binding was also visible in the GST only negative control (Fig. 2.16C). Hence, the DNA-binding domain 
together with the Transactivation domain, in particular proved to be highly important for the ability 
of p53 to interact with the HPV148 E6 protein.  
 
Figure 2.16: HPV148 E6 shows reduced binding capacity to p53 in the absence of the N-terminus and the 
DNA-binding domain of p53. 
(A) Schematic representation of the p53 protein. The p53 protein domains include the Transactivation domain 
(residues 20-60), the Proline-rich domain (residues 60-90), the sequence-specific core DNA-binding domain 
(residues 100-300), the Tetramerization domain (Tet domain, residues 325-356), and the lysine-rich C-terminal 
domain (residues 363-393). Figure adapted from Vousden and Prives [2009]. (B) GST-tagged HPV16 E6, 
HPV148 E6 or GST were incubated with in vitro translated 
35
S-radioactively labelled p53 constructs. GST and 
HPV16 were used as negative and positive controls, respectively. GST pull-down experiments were analysed by 
SDS-PAGE and Coomassie staining (lower panels). Gels were dried and exposed to X-ray films (Autoradiograms, 
upper panels). 10% of total 
35
S-radioactively labelled p53 was used as input. (C) A schematic overview of the 
in vitro transcribed and translated Flag-p53 constructs analysed in GST pull-down experiments.  
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2.4.3 HPV148 E6 protein co-localises with p53 in different cell lines 
The preceding experiments pinpointed the physiological importance of the interaction 
between p53 and HPV148 E6 proteins. In order to further gain insight into the interaction, the 
cellular localisation of both proteins was studied. Therefore, immunofluorescence analyses were 
performed (see section 5.5.7). In these experiments both, U2OS and H1299 cell lines were used, to 
analyse whether differences in the localisation pattern could be observed. First, the localisation of 
the p53 protein was analysed using a transiently transfected YFP-p53 expression plasmid or 
endogenous p53 by immunofluorescence microscopy. Then, the co-localisation of YFP-p53 and the 
HA-tagged HPV148 E6 was analysed. Immunofluorescence microscopy showed a strong nuclear 
localisation of YFP-tagged p53 protein, with an overall expression in a diffuse pattern in H1299 and 
U2OS cells (Fig. 2.17A). Endogenous p53 expression was only analysed in U2OS cells, as H1299 cells 
are a p53-null cell line. Here, p53 expression was again mainly nuclear, but the protein was also 
present in the cytoplasm in a diffuse expression pattern (Fig. 2.17B).     
In order to examine the cellular localisation of p53 in the presence of HPV148 E6 by means of 
immunofluorescence analyses, U2OS and H1299 cells were transfected with a combination of 
YFP-p53 and HA-tagged HPV148 E6 expression plasmids. Upon co-expression of both proteins, the 
distribution of each protein was not significantly changed in U2OS cells (Fig. 2.18, lower panel). Both 
proteins mainly co-localised in the nucleus, but they also did so in the cytoplasm. The pattern was 
diffuse, but co-localisation was also observed in speckles in both nucleus and cytoplasm. When 
co-expression of HPV148 E6 and YFP-p53 was performed in H1299 cells, the p53 expression pattern 
changed. Instead of localising mainly in the nucleus it switched to the cytoplasm, still maintaining a 
diffuse pattern. Hence, co-localisation of p53 and HPV148 E6 was mainly observed in the cytoplasm 
in H1299 cells (Fig. 2.18, upper panel), which stands in contrast to the U2OS cells. 
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Figure 2.17: p53 localisation in H1299 and U2OS cells. 
H1299 and/or U2OS cells were transiently transfected with (A) YFP-p53 or (B) stained for endogenous p53 and 
then detected by immunofluorescence microscopy. Nuclear DNA (blue) was stained with Hoechst. The 
localisation of p53 is presented in yellow (A) and green (B). The scale bar represents 10µm. 
 
 
Figure 2.18: p53 co-localises with HPV148 E6 in H1299 and U2OS cells. 
H1299 and U2OS cells were transiently transfected with YFP-p53 and HA-tagged HPV148 E6 and then detected 
by immunofluorescence microscopy. Nuclear DNA (blue) was stained with Hoechst. Co-localisation of 
HPV148 E6-HA (white) and YFP-p53 (yellow) is presented on merged images (orange). Nuclear DNA (blue) was 
stained with Hoechst. The scale bar represents 10µm. 
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2.4.4 The reporter activity of p53 is repressed upon expression of HPV148 E6 
The discovery that p53 binds and interacts with HPV148 E6 but not HPV23 E6 has never been 
reported before, still the question which function lies behind this interaction remains unanswered. 
To address this issue, luciferase reporter assays were performed using H1299 cells (see section 
5.5.8). There, increasing amounts of HA-tagged HPV148 E6 were transfected to determine its impact 
on p53 activity. In addition, HPV23 E6 was transfected and analysed as a negative control, since it did 
not interact with p53 in vivo in the previous experiments (Fig. 2.15B). The p53 promoter firefly 
construct was added to every reaction in equal amounts.  
Figure 2.19: HPV148 E6 represses p53 reporter activity. 
(A) Luciferase reporter assays in H1299 cells. Cells were transiently transfected with increasing amounts of HA-
tagged HPV23 E6 and HPV148 E6 expression plasmids as well as 5ng of firefly p53 promoter construct per 
reaction. Firefly luciferase activity (relative light units (RLU) normalised against renilla luciferase activity) is 
expressed as percentage of the signal obtained by transfecting no HPV E6 expression plasmid. Each bar 
represents the mean values plus standard deviation of four independent experiments. (B) H1299 cells were 
transiently transfected with increasing amounts of HA-tagged HPV148 E6 expression plasmid. Protein levels 
were analysed by Western blotting. Actin was used to assess equal loading. 
 
Remarkably, upon addition of only 0.5ng HA-tagged HPV148 E6 the activity of p53 was 
reduced by half to 52%. When increasing the HPV148 E6 dosage to 1ng p53 the activity was again cut 
in half to 26%. Finally, the highest amount of the E6 protein, namely 5ng resulted in a near complete 
reduction of p53 activity to 4% (Fig. 2.19A, left panel). On the contrary, only marginal reductions of 
the reporter activity could be observed for HPV23 E6 when using 0.5 and 1ng of the HA-tagged 
construct. After using 5ng of HPV23 E6 the activity of the p53 promoter dropped to about 71%, 
which remained minimal compared to the reduction when using the same amount of HPV148 E6 
(Fig. 2.19A, right panel). To rule out the possibility that expression of HA-tagged HPV148 E6 itself 
influenced p53 protein levels, H1299 cells were transfected with increasing amounts of the 
HPV148 E6 expression construct. Here, neither an increase nor a reduction of p53 protein expression 
was observed (Fig. 2.19B). These findings revealed a so far undescribed mechanism of HPV148 E6. It 
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was shown to not only be able to bind to p53 in vitro and in vivo, but it also repressed p53 promoter 
activity. 
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S e c t i o n 3 
 
 
Discussion 
 
Ultraviolet radiation and UVB in particular, is the major risk factor for the development of 
skin cancer. UVB light, in contrast to UVA, has a much higher phototoxic effect, since DNA directly 
absorbs incident photons from UVB [Rosenstein and Mitchell, 1987]. An important cellular 
mechanism to counteract the accumulation of multiple mutations, and in the last instance skin 
cancer development, is DNA repair [Ichihashi et al., 2003]. The importance of DNA repair 
mechanisms in the context of UV exposure has been well documented in Xerodema pigmentosum 
patients, who have a defective nucleotide excision repair mechanism and show hypersensitivity to 
sunlight combined with an increased incidence of skin cancer [Sijbers et al., 1996].  
Furthermore, a role for cutaneous beta HPV E6 proteins in the course of skin carcinogenesis 
has been predicted in several studies [Bouwes Bavinck et al., 2010; de Koning et al., 2009; Karagas et 
al., 2006; Struijk et al., 2003]. The E6 proteins of beta-HPV types have been described to activate 
telomerase and thereby prolong the life span of keratinocytes [Bedard et al., 2008]. Moreover, E6 
proteins can inhibit UV-induced apoptosis through the degradation of the pro-apoptotic protein Bak 
[Jackson et al., 2000] and the lack of p53 phosphorylation at serine 46 via binding of HIPK2 [Muschik 
et al., 2011]. However, only little is known about the exact role of cutaneous HPVs in skin cancer 
development, compared to mucosal HPVs and (ano)genital cancers. To gain more insight into 
virus/host interactions of novel cutaneous HPV E6 proteins with respect to e.g. DNA damage 
response, the analysis of new interaction partners of novel cutaneous HPV types was performed.  
This PhD thesis identifies the LIM protein Ajuba as a novel interaction partner for cutaneous 
HPV types of the beta2, gamma1 and gamma11 genera. Moreover, the present study describes for 
the first time that the p53 protein interacts with specific cutaneous HPV types, and is additionally 
repressed upon expression of the E6 protein from HPV148 (gamma11), suggesting a novel regulatory 
mechanism of cutaneous E6 proteins.  
 
3.1 Cutaneous HPV E6 proteins from the beta2, gamma1 and gamma11 
genera co-localise and interact with Ajuba  
The ability of the novel HPV E6 fusion proteins from different HPV genera to directly interact 
with the in vitro translated putative novel interaction partners identified for HPV4 E6 (PDCD6IP, 
Leupaxin, C9orf102 and Ajuba, see section 2.1.1) was analysed (Fig. 2.2). However, these interaction 
studies demonstrated that not all of the predicted interaction partners could be verified. The only 
protein that was confirmed to interact with certain cutaneous HPV E6 proteins both in vitro and in 
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vivo was Ajuba. Interestingly, only cutaneous E6 proteins from the beta (HPV23) and gamma genera 
(HPV4, HPV148) were found to interact with Ajuba, but not genital HPVs from the alpha genus 
(HPV16, HPV117) (Fig. 2.4 and Fig. 2.5). In order to map the binding region required for the 
interaction of HPV E6 with Ajuba, the binding of individual E6 proteins to in vitro translated Ajuba 
deletion mutants was analysed (Fig. 2.7). The region required for the binding of the beta and gamma 
HPV E6 proteins was identified to be the N-terminal part of the Ajuba protein, referred to as the 
PreLIM region. Whether all three E6 proteins from the beta and gamma genera interact with the 
same sequence was however not determined in the present thesis. To further map the specific 
interaction motif of individual HPV types, additional GST pull-down experiments need to be 
performed.  
Notably, the E6 protein of the genital HPV16 also interacted with Ajuba in vitro. In contrast 
to the cutaneous HPV E6 proteins which bound to the PreLIM region, HPV16 E6 interacted with the 
LIM region of Ajuba. This observation is in concordance with a previous report, where Zyxin, a 
member of the Ajuba/Zyxin protein family, was identified to interact specifically with the E6 protein 
of genital HPV6 through its LIM region. The interaction of Zyxin with HPV16 E6 or HPV18 E6 was 
however not significant [Degenhardt and Silverstein, 2001]. Nonetheless all three E6 proteins 
represent alpha PVs, indicating that the interaction of E6 proteins of alpha PVs with members of the 
Ajuba/Zyxin family differs from that of cutaneous HPVs. Furthermore, Ajuba was shown to interact 
with other proteins like the Aurora-A kinase or the tumour suppressor LATS2 through its LIM region 
[Abe et al., 2006; Hirota et al., 2003]. On the other hand, Ajuba’s PreLIM region was reported to 
associate with microtubules or the protein Grb2 [Ferrand et al., 2009; Goyal et al., 1999]. 
In this study, it was further demonstrated that Ajuba preferentially localises in the cytoplasm 
(Fig. 2.8B), as has been previously reported [Hirota et al., 2003; Hou et al., 2008; Kanungo et al., 
2000]. The E6 proteins of HPV23 and HPV148 preferentially localised to the nucleus but were also 
found in a diffuse distribution throughout the cytoplasm. The E6 proteins of HPV4 and HPV16, on the 
other hand, were predominantly detected in the cytoplasm (Fig. 2.8). Previous studies also reported 
that the E6 proteins of low-risk and cutaneous beta HPV types show largely nuclear expression 
patterns, while high-risk mucosal HPV E6 proteins are expressed much more diffusely throughout the 
cell [Guccione et al., 2002; Massimi et al., 2008; Sherman and Schlegel, 1996]. In this study, 
immunofluorescence analyses revealed that the overexpression of Ajuba resulted in the 
translocation and co-localisation of the HPV23 E6 and HPV148 E6 proteins in the cytoplasm (Fig. 2.9). 
Interestingly, this effect appeared to be characteristic for E6 of HPV23 and HPV148, since no 
co-localisation could be observed for HPV16 E6. Accordingly, these findings denote that the 
co-localisation of E6 proteins and Ajuba is mediated by their direct interaction. 
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In a previous report it was demonstrated that the co-transfection of HPV6 E6 and Zyxin 
resulted in the accumulation of both proteins in the nucleus. The study also pointed out that HPV6 E6 
was able to mobilise endogenous Zyxin into the nucleus [Degenhardt and Silverstein, 2001]. Although 
these data stand in contrast to the observed localisation pattern in the present study, the different 
outcomes can be explained by the already mentioned different functions of the Ajuba and Zyxin 
proteins. However, a study analysing the co-localisation of HPV E6 and p53 in transformed cell lines, 
showed that both proteins localise in the cytoplasm [Liang et al., 1993]. The HPV-negative cell line 
C-33 A displayed a predominantly nuclear localisation of p53. Therefore, co-localisation of an HPV E6 
protein with another cellular protein does not necessarily have to take place in the nucleus. 
However, the presented results demonstrated that HPV E6 proteins from the beta and gamma 
genera interact and co-localise with Ajuba. 
 
3.2 HPV23 E6 and HPV148 E6 proteins decrease in response to Ajuba 
knockdown and DNA damage 
In order to analyse Ajuba’s influence on the E6 proteins of HPV23 and HPV148, further 
experiments were performed. This study demonstrates that the beta2 HPV23 E6 and the gamma11 
HPV148 E6 proteins showed a reduced expression together with Ajuba in response to severe DNA 
damage, which was induced by either UVB radiation or ADR treatment in U2OS cells. Both 
treatments lead to the degradation of endogenous Ajuba as well as to the depletion of the respective 
E6 proteins (Fig. 2.13A and B). Similarly, siRNA-mediated down regulation of Ajuba led to a decrease 
in the protein levels of HPV23 E6 and HPV148 E6 (Fig. 2.12A and B), suggesting a close interaction 
between Ajuba and both E6 proteins in vivo. Additionally, a reduced protein expression of 
endogenous p53 was observed upon Ajuba siRNA knockdown in U2OS cells stably transfected with 
the E6 proteins of HPV23 and HPV148 (Fig. 2.12B) pointing to an additional role of p53 when 
expressed together with at least Ajuba, since p53 protein levels were also slightly reduced in the 
vector control lane. Furthermore, Ajuba’s ability to accumulate in response to the overexpression of 
HPV23 E6 and HPV148 E6 further hints at a close functional association of these proteins inside the 
cell (Fig. 2.11A and B), especially considering that Ajuba did not accumulate upon overexpression of a 
GFP construct containing the same promoter as the HPV E6 constructs (Fig. 2.11D). Moreover, 
HPV148 E6 was also able to accumulate upon Ajuba overexpression (Fig. 2.11C), indicating that the 
observed protein accumulations are mediated by a direct association of Ajuba and the HPV E6 
proteins. These observations, in particular the results of induced DNA damage (Fig. 2.13), do 
however not relate to a previously performed study, where the accumulation of HPV23 E6 after ADR 
treatment or UVB radiation was reported [Muschik et al., 2011]. This study was performed in H1299 
cells which lack endogenous p53, whereas in the presented study U2OS cells harbouring wild type 
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p53 were used, which might influence the results. Moreover, a similar effect as in the mentioned 
study was observed when using H1299 cells (data not shown); suggesting that the p53 protein affects 
the protein levels of Ajuba and HPV23 and HPV148 E6 proteins upon DNA damage.  
An additional adaptor protein might also play a role in E6 protein accumulation and the 
different response to DNA damage. Different studies propose a role for the Aurora-A kinase, an 
interaction partner of Ajuba, to induce Mdm2-mediated destabilisation and inhibition of p53 after its 
phosphorylation at Ser315 [Katayama et al., 2004]. Additionally, phosphorylation of p53 at Ser215 by 
Aurora-A was shown to abrogate its DNA binding and transactivation activity on downstream target 
genes such as p21Cip/WAF1 and PTEN [Liu et al., 2004]. Also, upon overexpression of Ajuba an increase 
in Aurora-A protein levels was observed (data not shown). The putative adaptor protein between p53 
and Ajuba could therefore be Aurora-A or any other interaction partner, associating with both 
proteins. 
Noteworthy is also the fact that the novel HPV148 genome was isolated from an actinic 
keratosis, a precursor of cutaneous SCC, making it additionally interesting to examine [Köhler et al., 
2011], as it might turn out to be a potential “high-risk” cutaneous HPV type. 
 
3.3 The effect of p53 on the complex of Ajuba and HPV23 E6/HPV148 E6 
p53 has an important function as a key regulator of apoptosis [Vousden, 2000]. In cancers 
however, its activity is often lost, either due to mutations in p53 itself, because of mutations of 
regulators upstream of p53 (e.g. CHK2, MDM2) or by disruption of the cell-growth-inhibition 
pathways that mediate the p53 response (e.g. by loss of components of the apoptotic cascade) 
[Vousden and Lu, 2002]. Binding of p53 followed by its degradation is a well described property of 
mucosal HPV E6 oncoproteins to inhibit apoptosis. This mechanism is however missing in their 
cutaneous counterparts [Doorbar et al., 2012; Elbel et al., 1997]. Nevertheless, cutaneous HPV E6 
proteins of the beta genus were shown to inhibit p53-mediated apoptosis after UVB-induced 
DNA-damage, through e.g. the inhibition of p53 phosphorylation at serine 46 via the interaction with 
the tumour suppressor HIPK2 [Mantovani and Banks, 2001; Muschik et al., 2011; Struijk et al., 2008]. 
The previously outlined evident involvement of p53 in the regulation of Ajuba and HPV E6 protein 
levels was further analysed in this study, revealing that p53 formed a trimeric complex with Ajuba 
and HPV148 E6, demonstrated by co-precipitation (Fig. 2.14B and D). However, p53 was excluded 
from the complex formation when using HPV23 E6 and Ajuba (Fig. 2.14A and C), even though a 
complex between HPV23 E6 and Ajuba was still formed (Fig. 2.14A) as already demonstrated in the 
initial experiments (Fig. 2.4B). Remarkably, a novel, so far undescribed interaction was observed 
between HPV148 E6 and p53 (Fig. 2.14D).  
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As already mentioned, preceding studies showed that cutaneous E6 proteins do not interact 
with p53 and do not induce ubiquitination or degradation of p53 [Elbel et al., 1997; Harry and 
Wettstein, 1996; Steger and Pfister, 1992]. However, HPV E6 proteins were demonstrated to bind to 
two sites within the p53 protein. One site lies within the core structure of p53 and the other one is 
found at the C-terminus of the protein. Yet, only the core binding is required for E6-mediated 
degradation of p53 [Li and Coffino, 1996]. Moreover, binding to p53 was suggested to be a 
prerequisite for the inhibition of p53-mediated transactivation, but does not appear to be sufficient 
for p53 degradation, a function of the ubiquitin ligase E6AP [Elbel et al., 1997]. To examine whether 
the observed interaction between HPV148 E6 and p53 was not only the result of a specific 
experimental setting, p53 binding was further analysed in vitro and in vivo. Surprisingly, the GST 
pull-down experiments not only revealed the in vitro interaction between HPV16 E6 and p53, but 
also between the E6 proteins of HPV23 and HPV148 with p53 (Fig. 2.15A). Nevertheless, as depicted 
in figures 2.14C and D, only HPV148 E6, but not HPV23 E6 was able to interact with p53 in vivo (Fig. 
2.15B and C). Additional experiments showed that Ajuba did not interact with p53 in the absence of 
E6 (Fig. 2.15D), pinpointing that the interaction of Ajuba with p53 can only take place in the complex 
with HPV148 E6. Figure 3.1 summarises all co-immunoprecipitation experiments performed in this 
study with regard to Ajuba involvement. To find out the exact order of the interaction, more complex 
co-immunoprecipitation experiments will have to be performed in the future.  
 
Figure 3.1: Schematic representation of Ajuba interactions with cutaneous HPV E6 proteins and p53. 
A model representing all analysed in vivo interactions of Ajuba detected by co-immunoprecipitation 
experiments, using two (A) or three (B) overexpressed proteins. 
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The cellular localisation of p53 and HPV148 E6 was analysed by immunofluorescence in 
U2OS and H1299 cells. Here, endogenous p53 was shown to localise mainly to the nucleus, although 
a diffuse expression in the cytoplasm could also be observed (Fig. 2.17B). Overexpressed YFP-p53 
primarily localised to the nucleus and was diffusely distributed in U2OS and H1299 cells (Fig. 2.17A). 
p53 is known to shuttle between the cytoplasm and the nucleus in a cell-cycle dependent manner 
[Hayon and Haupt, 2002]. After cellular stress p53 accumulates in the nucleus, an essential 
prerequisite for its biological effects to occur. The inhibition of p53 translocation to the nucleus 
results in the abrogation of many of its biological effects [O'Brate and Giannakakou, 2003]. In the 
presence of HPV148 E6, a co-localisation with p53 was mainly observed in the nucleus of U2OS cells 
(Fig. 2.18, lower panel). When co-expression was performed in H1299 cells, the co-localisation took 
place in the cytoplasm (Fig. 2.18, upper panel). 
To gain further insight into the function of the p53/HPV148 E6 interaction it was attempted 
to map the binding site of HPV148 E6 with p53 (Fig. 2.16). A strong binding of HPV148 E6 to 
full-length p53 was observed, which was further increased upon deletion of the C-terminus (Flag-p53 
1-298). When the N-terminal domains of p53 were deleted (Flag-p53 80-393) the binding of 
HPV148 E6 was weaker, but still present, indicating that binding was possible in principle, although 
the interaction site might not be fully accessible due to a different folding of the protein. When only 
the transactivation domain was present (Flag-p53 1-70), the binding of HPV148 E6 was completely 
abolished. However, when only the C-terminal part of p53 was present (Flag-p53 294-393), the 
binding of E6 was very weak and background binding was observed in the GST negative control (Fig. 
2.16C). The observed background binding further reduced the objective signal intensity of the 
HPV148 E6 band. Nevertheless, these results are consistent with the previous reports of two binding 
sites for HPV E6 proteins within the p53 protein [Li and Coffino, 1996]. In order to map the exact 
binding site of HPV148 E6 within p53 more deletion constructs containing deletions of the individual 
domains of p53 can be constructed and analysed in the future, for a clearer readout. Additionally, 
due to the novel finding of an interaction between p53 and HPV148 E6, experiments regarding the 
ability of the E6 protein to degrade p53 should also be performed. 
To further elucidate the physiological function of the interaction between HPV148 E6 and 
p53, luciferase reporter assays were performed, identifying the repression of p53 activity upon 
transfection of increasing amounts of HPV148 E6 (Fig. 2.19A). The reporter activity dropped 
drastically when even the smallest amounts of HPV148 E6 were introduced, whereas no such 
dramatic effect was obtained with HPV23 E6. Moreover, expression of the HPV148 E6 protein itself 
did not influence p53 protein levels (Fig. 2.19B), indicating that HPV148 E6 affected the 
transactivation activity of p53. This observation is a highly relevant finding in this study since the new 
interaction of HPV148 E6 with p53 not only takes place, but also strongly affects p53 activity (Fig. 
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2.19). Therefore, targeting of the transactivation activity of p53 by the cutaneous gamma11 type 
HPV148 might represent a mechanism whose physiological relevance for the virus is comparable to 
p53 inactivation by genital HPV types. 
 
3.4 Future perspectives 
Up to date, the involvement of cutaneous HPV types in the development of malignancies of 
the skin is still undefined, a fact that stimulates further investigations [Asgari et al., 2008; Muñoz et 
al., 2003; Zur Hausen, 2009]. In contrast, the etiologic relationship between cervical cancer 
development and infections with high-risk mucosal HPVs is well known. Nevertheless, an 
accumulating body of evidence supports a considerable role for cutaneous HPV types in combination 
with UV irradiation in the formation of skin cancer [Bouwes Bavinck et al., 2010; Jackson et al., 2000; 
Jackson and Storey, 2000; Struijk et al., 2008]. Up to now, only HPV5 and HPV8, both belonging to 
the beta1 genus, are considered to be “oncogenic cutaneous HPV types”, (similar to the mucosal 
high-risk HPVs), due to their association with the development of cutaneous SCC in EV patients 
[Akgül et al., 2010; Lutzner et al., 1980; Orth, 1986; Ramoz et al., 1999]. Although cutaneous high-risk 
HPV types have not been defined yet, the study at hand introduces an HPV type from the gamma11 
genus, which down regulates the transcriptional activity of p53, an important regulator of apoptosis. 
This interaction might have a strong impact on cell proliferation and cellular progression into 
malignancy.  
Future studies need to uncover the precise role of the interaction of HPV148 E6 with p53 and 
moreover to analyse Ajuba’s involvement in this process considering that additional binding partners 
might be involved. Further, to validate the biological significance of the research findings, primary 
human keratinocytes have to be employed, since the skin represents the natural host for cutaneous 
HPV infection and here cell lines derived from an osteosarcoma and non-small cell lung carcinoma 
were used [Doorbar et al., 2012]. Hence, the potential of HPV E6 proteins, of HPV148 E6 in particular, 
to facilitate the development of cutaneous lesions should be addressed. Thus, primary keratinocytes, 
infected with distinct HPV types or their respective E6 proteins, can be analysed after UVB radiation 
or Ajuba depletion under physiological conditions, especially if organotypic skin culture systems are 
used. Another approach would be the use of transgenic animals expressing preferentially the E6 
genes of cutaneous HPV types, or additionally lacking Ajuba. There, the role of UVB radiation and/or 
chemically induced skin carcinogenesis in the development of skin tumours can be tested, as has 
been already successfully shown for HPV 38 [Viarisio et al., 2011; Viarisio et al., 2013]. In summary, 
the present study strengthens the hypothesis that cutaneous HPVs can act as co-factors in the 
development of skin cancer either in association with UVB radiation or through the interaction with 
other cellular target proteins. Thus, additional studies should continue focussing on cutaneous HPVs, 
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which (in case of HPV148) will greatly contribute to the knowledge of the complex cellular network of 
gamma-PVs. 
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S e c t i o n 4 
 
 
Material 
 
4.1 Chemicals and Reagents 
 
4.1.1 Chemicals, solutions, and reagents 
 
Table 4.1: Chemicals 
Chemical Distributor 
2-Mercaptoethanol Sigma-Aldrich, Steinheim 
Acetic acid, p.a. (100 %) Merck, Darmstadt 
Acrylamide/bis Acrylamide (29:1), 30 % solution SERVA Electrophoresis, Heidelberg 
Agarose Sigma-Aldrich, Steinheim 
Albumin bovine (BSA) Fraction V Biomol Hamburg 
Ammonium persulfate (APS) Sigma-Aldrich, Steinheim 
AmplifyTM Fluorographic Reagent GE Healthcare, Munich 
Aqua ad iniectabilia Braun, Melsungen 
Beta-Glycerophosphate AppliChem GmbH, Darmstadt 
Bisbenzimide (Hoechst 33258) Sigma-Aldrich, Steinheim 
Bromophenol blue Sigma-Aldrich, Steinheim 
Complete protease inhibitor, EDTA-free Roche Diagnostics, Mannheim 
Coomassie G-250 Sigma-Aldrich, Steinheim 
DMSO Merck, Darmstadt 
DNA loading buffer (6x) Fermentas, St. Leon-Rot 
dNTPs set PCR grade Invitrogen, Karlsruhe 
ECL SuperSignal West Dura Thermo Fischer Scientific, USA 
EDTA Roche Diagnostics, Mannheim 
Ethanol, p.a. Sigma-Aldrich, Steinheim 
Ethidium bromide solution, 1% Sigma-Aldrich, Steinheim 
Formaldehyde Merck, Darmstadt 
Glucose Carl Roth GmbH, Karlsruhe 
Glutathione SepharoseTM 4FastFlow beads GE Healthcare, Munich 
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Table 4.1: Chemicals (continued) 
Chemical Distributor 
Glycerol, p.a. (99.5%) Carl Roth GmbH, Karlsruhe 
Glycine  GERBU Biotechnik GmbH, Heidelberg 
HEPES Eurobio, France 
Hydrochloric acid Merck, Darmstadt 
Isopropyl alcohol, p.a. Merck, Darmstadt 
KCl Merck, Darmstadt 
KH2PO4 Carl Roth GmbH, Karlsruhe 
L-[35S]-methionine, 10mCi/mL Perkin Elmer, Jügesheim 
Magnesium chloride (MgCl2) Merck, Darmstadt 
Magnesium sulphate (MgSO4) Merck, Darmstadt 
Methanol, p.a. Merck, Darmstadt 
MG-132 (Z-Leu-Leu-Leu-al) Enzo Life Sciences, Lörrach 
Mowiol 4-88 Carl Roth GmbH, Karlsruhe 
Na2HPO4 Carl Roth GmbH, Karlsruhe 
NaOH Carl Roth GmbH, Karlsruhe 
Nonidet® P40 (NP40) AppliChem GmbH, Darmstadt 
PMSF Roche Diagnostics, Mannheim 
Powdered milk, blotting grade Carl Roth GmbH, Karlsruhe 
Protein A/G PLUS-Agarose beads Santa Cruz, Heidelberg 
RNase OUT™ Recombinant Ribonuclease Inhibitor Invitrogen, Karlsruhe 
Sodium acetate Merck, Darmstadt 
Sodium chloride, p.a. (NaCl) Merck, Darmstadt 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Steinheim 
Sodium fluoride Merck, Darmstadt 
Sodium ortho-vanadate (Na3VO4) Sigma-Aldrich, Steinheim 
TEMED Sigma-Aldrich, Steinheim 
Trizma® base Sigma-Aldrich, Steinheim 
Triton® X-100 AppliChem GmbH, Darmstadt 
Tween 20  Sigma-Aldrich, Steinheim 
Western Lightning Plus-ECL Perkin Elmer, Jügesheim 
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4.1.2 Reagents for bacteria cultivation 
 
Table 4.2: Bacteria culture reagents 
Reagent Distributor 
Ampicillin Sigma-Aldrich, Steinheim 
BactoTM Agar Becton Dickinson, Heidelberg 
BactoTM Trypton Carl Roth, Karlsruhe 
Isopropyl-beta-D-thiogalactopyranoside (IPTG) AppliChem GmbH, Darmstadt 
Chloramphenicol Sigma-Aldrich, Steinheim 
Kanamycin Sigma-Aldrich, Steinheim 
LB-Medium (Lennox) Carl Roth, Karlsruhe 
Sodium chloride, p.a. Merck, Darmstadt 
Terrific-Broth Medium Carl Roth, Karlsruhe 
Yeast extract GERBU Biotechnik GmbH, Heidelberg 
 
4.1.3 Reagents for cell culture 
 
Table 4.3: Cell culture reagents 
Reagent Distributor 
Adriamycin (ADR) Tebu-Bio, Offenbach 
Dulbecco’s modified Eagle’s medium (DMEM) Sigma-Aldrich, Steinheim 
Dulbecco’s Phosphate Buffered Saline (PBS) Gibco Life Technologies, Karlsruhe 
DMSO, sterile Merck, Darmstadt 
Effectene Transfection Reagent Qiagen, Hilden 
Fetal Bovine Serum (FCS) Linaris GmbH, Wertheim 
Geneticin (G418) solution PAA Laboratories, Austria 
Lipofectamine 2000 Transfection Reagent Invitrogen, Karlsruhe 
Opti-MEM serum-free medium Gibco Life Technologies, Karlsruhe 
Trypsin/EDTA (0.25%) Gibco Life Technologies, Karlsruhe 
 
4.2 Consumables 
 
Table 4.4: Consumables 
Item Distributor 
Amersham Hybond™-P (PVDF membrane) GE Healthcare, Munich 
Cell culture flasks (25, 75 cm2) Corning Sigma, Munich 
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Table 4.4: Consumables (continued) 
Item Distributor 
Cell culture dishes/plates TPP, Switzerland 
CoolCell® -1 °C/min Cell Freezer SERVA Electrophoresis, Heidelberg 
Cover slides Thermo Fisher Scientific, Rockslide 
Cryo-tubes (2 mL) Greiner Bio-One, Frickenhausen 
Cuvettes BRAND GMBH + CO KG, Wertheim 
Gloves (Blossom Latex Gloves, S) Mexpo International, USA 
Gloves (Dermatril®M)  KCL GmbH, Eichenzell 
Microplates 96 well Greiner Bio-One, Frickenhausen 
Object glass slides Langenbrinck, Emmendingen 
Parafilm Pechinery Inc., USA 
Pasteur pipettes Brand, Wertheim 
Petri dishes (for Agar plates) Greiner Bio-One, Frickenhausen 
Pipette tips (10, 100, 1000 µL) Greiner Bio-One, Frickenhausen 
PCR Soft strips Biozym, Oldendorf 
Polypropylene conical tubes (15, 50 mL) Greiner Bio-One, Frickenhausen 
Reaction tubes (0.5, 1.5, 2.0 mL) Eppendorf, Hamburg 
Saran wrap Cofresco Frischhalteprodukte, Minden 
Scalpels, disposable Feather Safety Razor, Japan 
Sterile filters (0.22 µm) Millipore, Schwalbach 
TipOne Filter Tips (10, 200, 1000 µL) StarLab, Ahrensburg 
Whatman 3MM filter paper Schleicher & Schüll, Dassel 
X-ray films, Super RX Fuji, Japan 
 
4.3 Laboratory equipment 
 
Table 4.5: Instruments and laboratory equipment 
Instrument Distributor 
Agarose gel electrophoresis chambers Renner, Darmstadt 
Analytical balance scale 2004 MP Sartorius, Göttingen 
Analytical scale, Acculab VIC-212 Sartorius, Göttingen 
Autoradiography cassettes  Kodak, Stuttgart 
Bacteria shaker G25 Infors, Switzerland 
Balance 1216 MP Julabo, Seelbach 
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Table 4.5: Instruments and laboratory equipment (continued) 
Instrument Distributor 
Camera, UV light Renner, Darmstadt 
Centrifuge Biofuge fresco 17 Heraeus, Hanau 
Centrifuge Biofuge pico Heraeus, Hanau 
Centrifuge Megafuge 1.0R Heraeus, Hanau 
Centrifuge RC5C Sorvall DuPont, Bad Nauheim 
Developing machine CURIX 60 AGFA, Cologne 
Duran® glassware SCHOTT, Croatia 
ELISA reader Labsystem Multiscan Thermo Fisher Scientific, USA 
Freezer (-80°C, VIP series) Sanyo, Munich 
Geiger counter LB 1210B Berthold, Wildbad 
Gel dryer model 583 Bio-Rad Laboratories, Munich 
Hotplate/stirrer VWR, Darmstadt 
Incubator Labotec, Göttingen 
Magnetic stirrer MR 3001 Heidolph, Rust 
Microscope FLUOVIEW FV1000 Confocal Laser Olympus GmbH, Hamburg 
Microwave AEG, Nürnberg 
Minifuge Heraeus, Hanau 
Mini-PROTEAN® II Bio-Rad Laboratories, Munich 
Mini-PROTEAN® Tetra Cell Bio-Rad Laboratories, Munich 
MyCycler Thermal Cycler Bio-Rad Laboratories, Munich 
Neubauer hemocytometer Bender & Hobein, Bruchsal 
Nitrogen tank (ADUR β) Messer Griesheim, Krefeld 
Overhead shaker REAX2 Heidolph, Rust 
pH-meter Calimatic 765 Knick, Egelsbach 
Pipettes Eppendorf, Hamburg 
Pipetboy acu Integra Bioscience, Fernwald 
Power supply Power Pac HC Bio-Rad Laboratories, Munich 
Rotating wheel Neolab, Heidelberg 
Rotors Sorvall GS-3, SA 600, SS 34 DuPont, Bad Nauheim 
Sonifier 250 Branson/Heinemann, Schwäbisch Gemünd 
Spectrophotometer NanoDrop® ND-1000 NanoDrop, USA 
SterilBioGARD Hood Baker Company, USA 
Thermomixer Eppendorf, Hamburg 
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Table 4.5: Instruments and laboratory equipment (continued) 
Instrument Distributor 
UV table N90 Benda Konrad, Wiesloch 
Variocontrol UV-meter Waldmann, Villingen 
Vortexer Heidolph, Rust 
Waldmann UV181 BL UV-table Waldmann, Villingen 
Water bath JULABO GmbH, Seelbach 
Wet blot Western blotting chamber Bio-Rad Laboratories, Munich 
 
4.4 Buffers and solutions 
 
Table 4.6: Buffers and stock solutions 
Solution/Buffer Composition 
Ammonium persulfate (APS) 10% (w/v), store at -20°C 
Ampicillin (1000x) 100 mg/mL, store at -20°C 
Blocking buffer for Western blotting 5% (w/v) Milk powder in 1x TBST 
BSA solution 1 mg/mL, store at -20°C 
Cell culture freezing medium 60% (v/v) DMEM 
30% FCS 
10% DMSO 
Chloramphenicol (1000x) 34 mg/mL in methanol, store at -20°C 
Coomassie staining solution for SDS gels 50% methanol 
10% acetic acid 
40% ddH2O 
0.1% Coomassie G-250 
Denaturing lysis buffer 20mM Tris, pH 8.0 
1% NP40 
0.15M NaCl 
5mM EDTA 
10% glycerol 
1% SDS  
freshly supplemented with protease and 
phosphatase inhibitors and MG-132 
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Table 4.6: Buffers and stock solutions (continued) 
Solution/Buffer Composition 
Fixation/destain solution for SDS gels 50% methanol 
10% acetic acid 
40% ddH20 
In vitro interaction buffer 0.05% NP40 
1mM Na3VO4 
in PBS 
Kanamycin (1000x) 50 mg/mL, store at -20°C 
Laemmli buffer (10x) 0.25M Tris 
1.9M glycine 
1% (w/v) SDS 
LB-Agar plates 2% Bacto-Agar/1L LB-Medium 
LB-Medium (Lennox) 10g NaCl 
10g Bacto-Trypton 
5g yeast extract 
ad 1000mL H2O 
Mowiol 2.4g Mowiol 4-88 
6g glycerol 
12mL 0.2M Tris-HCl, pH 8.5 
6 mL ddH2O 
Non-denaturing lysis buffer 20mM HEPES 
0.15M NaCl 
5mM EDTA 
10% glycerol 
0.5% Triton X-100 
freshly supplemented with protease and 
phosphatase inhibitors, and MG-132 
PBS (10x) 1.24M NaCl 
0.22M Na2HPO4 
0.1M KH2PO4 
adjust to pH 7.8 
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Table 4.6: Buffers and stock solutions (continued) 
Solution/Buffer Composition 
SDS-loading buffer (5x) 10% (w/v) SDS 
0.03% (w/v) bromophenol blue 
12.5% (v/v) 2-mercaptoethanol 
5mM EDTA, pH 8.0 
50% (v/v) glycerol 
0.3M Tris, pH 6.8 
store at -20°C 
SOC-Medium 2% (w/v) Bacto-Trypton 
0.5% (w/v) yeast extract 
10mM NaCl 
2.5mM KCl 
10mM MgCl2 
10mM MgSO4 
20mM glucose 
TAE Buffer (50x) 2M Tris Base 
0.25M Sodium acetate 
0.05M EDTA, pH 8.0 
adjust to pH 7.8 with acetic acid 
TBS (10x) 0.1M Tris 
1.37M NaCl 
adjust to pH 7.6 
TBST (1x) 1x TBS, pH 7.6 
0.1% (v/v) Tween 20 
Towbin buffer (10x) 0.25M Tris 
1.92M glycine 
 
4.5 Molecular weight markers  
 
Table 4.7: Molecular weight markers  
Marker Distributor 
Gene Ruler™ 1kb DNA Ladder Fermentas, St. Leon-Rot 
Page Ruler™ Plus Prestained Protein Ladder Fermentas, St. Leon-Rot 
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4.6 Universal enzymes  
 
Table 4.8: Universal enzymes 
Enzyme Distributor 
FastAP alkaline phosphatase Fermentas, St. Leon-Rot 
Taq DNA polymerase Invitrogen, Karlsruhe 
PRECISOR High Fidelity DNA polymerase BioCat, Heidelberg 
TNT® T7 polymerase Promega, Mannheim 
T4 DNA Ligase Fermentas, St. Leon-Rot 
 
4.7 Restriction enzymes  
 
Table 4.9: Restriction enzymes 
Enzyme Distributor 
BamHI New England Biolabs, Schwalbach 
EcoRI New England Biolabs, Schwalbach 
NotI New England Biolabs, Schwalbach 
XhoI New England Biolabs, Schwalbach 
 
4.8 Antibodies 
 
Table 4.10: List of antibodies used for Western blot analyses, immunofluorescence experiments and 
co-immunoprecipitation experiments  
Antibody Supplier Catalogue № Application 
Anti-Actin (Clone 4)  
mouse monoclonal IgG 
MP Biomedical 691001 WB 1:10,000 
in 5% milk/TBST 
Anti-Ajuba Cell Signaling, USA 4897S WB 1:1,000 
in 5% BSA/TBST 
Anti-Flag M2 
mouse monoclonal IgG1 
Sigma, USA F 3165 WB 1:5,000 
in 5% milk/TBST 
Co-IP [3µg] 
Anti-GFP (FL)  
rabbit polyclonal IgG1 
Santa Cruz, 
Heidelberg 
sc-8334 WB 1:1,000 
in 5% milk/TBST 
Anti-GFP Roche Diagnostics 11 814 460 001 Co-IP [1µg] 
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Table 4.10: List of antibodies used for Western blot analyses, immunofluorescence experiments and 
co-immunoprecipitation experiments (continued) 
Antibody Supplier Catalogue № Application 
Anti-HA (12CA5)  
mouse monoclonal IgG2b 
Roche Diagnostics 11 583 816 001 IF 1:150  
in 1% BSA/PBS 
Co-IP [5µg] 
Anti-HA (3F10)  
rat monoclonal IgG1 
Roche Diagnostics 11867423001 WB 1:1,000 
in 5% milk/TBST 
Anti-p53 (DO-1)  
mouse monoclonal IgG2a 
Santa Cruz, 
Heidelberg 
sc-126 WB 1:1,000 
in 5% milk/TBST 
Anti-PARP-1 (F2) Santa Cruz, 
Heidelberg 
sc-8007 WB 1:1,000 
in 5% milk/TBST 
Goat anti-mouse IgG (H+L) 
HRP 
Jackson 
ImmunoResearch, USA 
115-035-062 WB 1:10,000 
in 5% milk/TBST 
Goat anti-rabbit IgG (H+L) 
HRP 
Jackson 
ImmunoResearch, USA 
111-035-144 WB 1:10,000 
in 5% milk/TBST 
Goat anti-rat IgG (H+L) HRP Jackson 
ImmunoResearch, USA 
112-035-143 WB 1:10,000 
in 5% milk/TBST 
Goat anti-mouse IgG1 
Alexa Fluor® 488 
Invitrogen, Karlsruhe A21121 IF 1:450 
in 1% BSA/PBS 
Goat anti-mouse IgG2a 
Alexa Fluor® 488 
Invitrogen, Karlsruhe A21131 IF 1:450  
in 1% BSA/PBS 
Goat anti-mouse IgG2a 
Alexa Fluor® 594 
Invitrogen, Karlsruhe A21135 IF 1:450  
in 1% BSA/PBS 
Goat anti-mouse IgG2b 
Alexa Fluor® 594 
Invitrogen, Karlsruhe A21145 IF 1:450  
in 1% BSA/PBS 
Goat anti-rabbit IgG 
Alexa Fluor® 488 
Invitrogen, Karlsruhe A11008 IF 1:450  
in 1% BSA/PBS 
 
4.9 Kits 
 
Table 4.11: Commercial kits 
Kit Distributor 
BCA Protein Assay Kit Thermo Fisher Scientific, USA 
Dual-Luciferase® Reporter Assay System Promega, Mannheim 
One Shot® TOP10 chemically competent E.coli Invitrogen, Karlsruhe 
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Table 4.11: Commercial kits (continued) 
Kit Distributor 
PureLINK™ Quick Plasmid Miniprep Kit Invitrogen, Karlsruhe 
QIAEX II Gel Extraction Kit Qiagen, Hilden 
QIAquick Gel Extraction Kit Qiagen, Hilden 
QIAGEN Plasmid Midi Kit Qiagen, Hilden 
QIAprep Spin Miniprep Kit Qiagen, Hilden 
TNT® Coupled Reticulocyte Lysate System Promega, Mannheim 
 
4.10 Oligonucleotides 
 
4.10.1 PCR primers 
 
Table 4.12: Oligonucleotide primers for the construction of different plasmids 
Listed are the primer pairs and separate primers for the construction of the respective plasmids in 4.12. Bold 
blue regions highlight the sequence of the respective restriction enzymes (Linker). Kozak sequences are marked 
in green, start codons in magenta and stop codons are shown in red. 
Primer name Sequence Linker 
Ajuba orf FW 5’-GCATCACTCGAGACCATGGAGCGGTTAGGAGAG-3’ XhoI 
Ajuba orf RV 5’-AGTCACGCGGCCGCTCAGATATAGTTGGCAGG-3’ NotI 
Ajuba LIM FW 5’-GCATCACTCGAGACCATGTGTATCAAGTGCAACAAAGGC-3’ XhoI 
Ajuba PreLIM RV 5’-AGTCACGCGGCCGCTCAGAAGTAGTCCTCCCT-3’ NotI 
LPXN orf FW 5’-GCATCAGCGGCCGCATGGAAGAGTTAGAT -3’ NotI 
LPXN orf RV 5’-AGTCACGGATCCCTACAGTGGGAAGAGCTTATT-3’ BamHI 
pCMV-Ajuba orf FW 5’-GCATCAGGATCCACCATGGAGCGGTTAGGA-3’ BamHI 
pCMV-Ajuba orf RV 5’-AGTCACCTCGAGTCAGATATAGTTGGCAGGGGGTTG-3’ XhoI 
pCMV-C9orf102 FW 5’-GCATCAGGATCCACCATGAAATGTTCAAATGAGAAAGTT-3’ BamHI 
pCMV-C9orf102 RV 5’-AGTCACCTCGAGTTATGTGGTACTCTGTGTATTGGT-3’ XhoI 
pGEX-HPV16 E6 FW  5`-GCATCAGGATCCATGCACCAAAAGAGAACT-3’ BamHI 
pGEX-HPV16 E6 RV 5`-AGTCACCTCGAGTTACAGCTGGGTTTCTCT-3’ XhoI 
pGEX-HPV117 E6 FW 5`-GATCGAATTCGCCATGTCTATGGGTGCACAA-3’ EcoRI 
pGEX-HPV117 E6 RV 5`-ATACCTCGAGCTAAGGGATGCGGACCGT-3’ XhoI 
pGEX-HPV118 E6 FW  5`-GCATCAGGATCCATGGAGGAGTATCCTATG-3’ BamHI 
pGEX-HPV118 E6 RV 5`-AGTCACCTCGAGTTATTTACAAAACTTACAAAGACC-3’ XhoI 
pGEX-HPV134 E6 FW  5`-GCATCAGGATCCATGGAACCAGTCTATTCT-3’ BamHI 
pGEX-HPV134 E6 RV 5`-AGTCACCTCGAGTTATTTTTTCCTACATAATCTACA-3’ XhoI 
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Table 4.12: Oligonucleotide primers for the construction of different plasmids (continued) 
Primer name Sequence Linker 
pGEX-HPV148 E6 FW  5`-GCATCAGGATCCATGGAGACCCCAACAGGA -3’ BamHI 
pGEX-HPV148 E6 RV 5`-AGTCACCTCGAGTTATTTCTGAGCACAATTTCTGCA-3’ XhoI 
pPK-HPV4 E6 FW K 5’-GCATCACTCGAGGCCATGGCAGATGGCAGA-3’ XhoI 
pPK-HPV4 E6 RV K 5’-AGTCACGGATCCTTGTTTCCTAATACAATTTCTGCA ATAGCC-3’ BamHI 
pPK-HPV117 E6 FW 5’-GATCGAATTCGCCATGTCTATGGGTGCACAA-3’ EcoRI 
pPK-HPV117 E6 RV 5’-ATACGGATCCAGGGATGCGGACCGT-3’ BamHI 
pPK-HPV148 E6 FW K 5’-GCATCACTCGAGGCCATGGAGACCCCAACAGGA-3’ XhoI 
pPK-HPV148 E6 RV K 5’-AGTCACGGATCCTTTCTGAGCACAATTTCTGCAATCTCC-3’ BamHI 
 
4.10.2 RNA oligonucleotides for RNA interference (RNAi) 
 
Table 4.13: Oligonucleotides for the siRNA-mediated knock-down experiments 
siRNA Target sequence Manufacturer Reference 
siAjuba 5’-GGGGCGCCUAAGUGGGUUG-dTdT-3’ Dharmacon, USA Hirota et al. [2003] 
siScramble 5’-AACAGUCGCGUUUGCGACUGG-dTdT-3’ Dharmacon, USA Schneider et al. 
[2006] 
 
4.11 Provided plasmids 
 
Table 4.14: Commercially available and provided expression plasmids 
Plasmid name Backbone/Properties Reference 
JUB Gateway Full ORF clone Full CDS of human Ajuba DKFZ, Heidelberg 
Flag-p53 pcDNA3.1 (-) Dr. T. G. Hofmann (DKFZ, Heidelberg) 
Flag-p53 1-70 pcDNA3.1 (-) Dr. T. G. Hofmann (DKFZ, Heidelberg) 
Flag-p53 1-298 pcDNA3.1 (-) Dr. T. G. Hofmann (DKFZ, Heidelberg) 
Flag-p53 80-393 pcDNA3.1 (-) Dr. T. G. Hofmann (DKFZ, Heidelberg) 
Flag-p53 294-393 pcDNA3.1 (-) Dr. T. G. Hofmann (DKFZ, Heidelberg) 
LPXN Gateway Full ORF 
clone 
Full CDS of human Leupaxin DKFZ, Heidelberg 
PDCD6 Gateway Full ORF 
clone 
Full CDS of human PDCD6 DKFZ, Heidelberg 
pEGFP - Clontech 
pEYFP-p53 pEYFP Dr. T. G. Hofmann (DKFZ, Heidelberg) 
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4.12 Cloned plasmids 
 
Table 4.15: Plasmids used for cloning purposes 
For the cloning of the GST-tagged HPV E6 fusion proteins, the vector pGEX-4T1 was used. For C-terminally 
HA-tagged HPV E6 proteins, the vector pPK-CMV-E3 was used. For the cloning of Flag-tagged expression 
proteins, the vector pCMV3-Tag-1 was used. The vector pcDNA3.1 (-) was used for the cloning of constructs for 
the in vitro transcription/translation of proteins. The available promoters and tags are represented in italic. 
IPTG: Isopropyl-beta-D-thiogalactopyranosid; GST: glutathione S-transferase; HA: hemagglutinin; CMV: 
cytomegalovirus 
Plasmid name Description Reference 
pcDNA3.1 (-) Promoter: CMV promoter Invitrogen, Karlsruhe 
pCMV3-Tag-1 Promoter: CMV promoter 
Tag: N-terminal 3x Flag-tag 
Agilent Technologies 
pGEX-4T1 Promoter: IPTG-inducible tac 
promoter 
Tag: N-terminal GST-tag 
GE Healthcare 
pPK-CMV-E3 Promoter: CMV promoter and 
enhancer 
Tag: C-terminal HA-tag 
PromoKine 
 
 
Figure 5.1: Maps of vector backbone and constructed expression plasmid. 
Depicted are general features of the empty pGEX-4T1, pPK-CMV-E3 and pCMV3-Tag-1 vectors (upper panel). A 
representative example for the constructed expression plasmids in this thesis are shown in the lower panel. 
pCMV: CMV promoter; HA: hemagglutinin tag; 3xFlag: 3x Flag tag; ptac: tac promoter; Neo/Kan/Amp: 
resistance cassette 
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4.13 Mammalian cell lines 
 
Table 4.16: List of human cell lines used throughout the presented thesis 
Cell line Characteristics Reference 
C-33 A Species: Homo sapiens (human) 
Tissue: epithelial; cervical carcinoma 
Comment: tumourigenic, HPV-negative, mutant p53, mutant 
pRb 
Crook et al. 
[1991] 
CaSki Species: Homo sapiens (human) 
Tissue: epithelial; cervical carcinoma 
Comment: tumourigenic, HPV16-positive (ca. 600 copies per 
cell) 
Pattillo et al. 
[1977] 
H1299 Species: Homo sapiens (human) 
Tissue: epithelial; non-small cell lung carcinoma 
Comment: homozygous partial deletion of the p53 protein, lack 
of p53 protein expression 
Radhakrishna 
Pillai et al. 
[2004] 
HeLa Species: Homo sapiens (human) 
Tissue: epithelial; cervical adenocarcinoma  
Comment: tumourigenic, HPV18-positive 
Jones et al. 
[1971] 
HPKn Species: Homo sapiens (human) 
Tissue: primary keratinocytes; neonatal foreskin 
Life 
Technologies 
Cat#: C001-5C 
NIKS   Species: Homo sapiens (human) 
Tissue: keratinocytes 
Comment: spontaneously immortal, extra isochromosome of 
the long arm of chromosome 8 
Allen-Hoffmann 
et al. [2000] 
SiHa Species: Homo sapiens (human) 
Tissue: epithelial; cervical squamous cell carcinoma 
Comment: tumourigenic, HPV16-positive (1-2 copies per cell) 
Friedl et al. 
[1970] 
SK-MEL-28 Species: Homo sapiens (human) 
Tissue: malignant melanoma 
Carey et al. 
[1976] 
U2OS Species: Homo sapiens (human) 
Tissue: epithelial; osteosarcoma 
Comment: expression of wt p53 protein 
Heldin et al. 
[1986] 
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4.14 Bacterial strains 
 
Table 4.17: Chemically competent bacteria 
The E. coli One Shot® TOP10 cells were purchased from Invitrogen and used for cloning purposes. The E. coli 
Rosetta strain was kindly provided by Prof. I. Hoffmann (DKFZ, Heidelberg) and used for the expression of 
GST-tagged proteins. 
Name Genotype Reference 
E. coli One Shot® TOP10  
(DH10B™) 
F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZ 
ΔM15 ΔlacX74 recA1 araD139 Δ (araleu) 
7697 galU galKrpsL (Str
R
) endA1 nupG 
Invitrogen, Karlsruhe 
E. coli Rosetta F- ompT hsdSB(rB
- mB
-) gal dcm pRARE 
(CamR) 
Prof. I. Hoffmann  
(DKFZ, Heidelberg) 
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S e c t i o n 5 
 
 
Methods 
 
5.1 Preparation, analysis, and cloning of nucleic acids 
 
5.1.1 Generation of PCR products for cloning 
The polymerase chain reaction (PCR) is a widely used in vitro technique for the selective 
amplification of specific regions from a DNA template. For cloning purposes, various viral E6 open 
reading frames (ORFs) as well as ORFs from other proteins were amplified by PCR using the 
respective templates. Forward and reverse primers were selected to harbour specific recognition 
sites for restriction enzymes (see section 4.12). The PCR reactions were performed using the 
proof-reading PRECISOR High-Fidelity DNA polymerase (BioCat). The following reagents were used in 
a total volume of 50µL in the MyCycler thermal cycler (Bio-Rad): 
50-100ng plasmid DNA containing the respective sequence 
10µL 5x HiFi reaction buffer (incl. 2mM MgCl2) 
0.5µL dNTP mix (25mM each) 
1µL primers (20µM each) 
1 Unit PRECISOR DNA polymerase 
ad 50µL water (ddH2O) 
Due to the 3’-5’ exonuclease activity of the DNA polymerase, the enzyme was added last to 
the reaction mixture in order to prevent primer degradation. All PCR reactions were performed using 
the following PCR program: 
                   Table 5.1: Standard cycling conditions 
Cycle Step Temperature Time Cycle(s) 
Initial denaturation 98°C 1 min 1 
Denaturation 98°C 30 sec 
35 Annealing Tan°C 30 sec 
Extension 72°C 30 sec/kb 
Final extension 72°C 10 min 1 
Cooling 4°C ∞  
 
After DNA amplification, the PCR reaction was directly digested using the respective 
restriction enzymes. It was then run on an agarose gel and subsequently purified (see sections 5.1.2 
and 5.1.4). 
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5.1.2 DNA agarose gel electrophoresis 
DNA agarose gel electrophoresis is an extensively used technique for the electrophoretic 
separation ad analysis of nucleic acids. Thereby, DNA can be characterised according to its size and 
conformation. Applying an electric field, the negatively charged DNA migrates through the agarose 
matrix. The concentration of agarose in the agarose gels varied between 0.5 and 2%/TAE (w/v), 
depending on the expected size of the DNA fragments. The DNA was visualised under UV light 
(260nm) using the intercalating agent ethidium bromide (1µg/mL), which was added to the liquid 
agarose solution before polymerisation and electrophoresis. 
  
5.1.3 Restriction enzyme digestion and dephosphorylation of plasmid DNA 
Analytical and preparative enzymatic DNA digestions were performed using bacterial type II 
restriction endonucleases according to the manufacturer’s instructions. An analytical digestion 
contained 1µg of plasmid DNA in a total reaction volume of 20-30µL. For preparative purposes, the 
DNA was linearised using the respective restriction enzymes. Thereby it obtained sticky ends 
compatible with the respective linearised cloning vector. PCR products or up to 10µg of plasmid DNA 
were digested in a total volume of 100µL, dephosphoralyted and purified after agarose gel 
electrophoresis. 
To prevent re-ligation of the digested plasmid DNA, a dephosphorylation reaction was 
performed. This incubation with an alkaline phosphatase removed the terminal 5’-phosphate group 
of the linearised plasmid DNA, thereby minimising spontaneous re-ligations of the cloning vector. 
Therefore the digested plasmid DNA was incubated with the FastAP alkaline phosphatase 
(Fermentas) according to the manufacturer’s instructions. Subsequently, the dephosphorylated 
plasmid DNA was run on an agarose gel and purified by gel extraction (see section 5.1.4). 
 
5.1.4 Extraction and purification of DNA from agarose gels 
For cloning, bands, of the digested and electrophoretically separated PCR products or 
plasmid DNA, were cut from the agarose gel using sterile scalpels under low energy UV light (366nm). 
Subsequently, DNA extraction and purification was performed from the gel slices using a Qiagen gel 
extraction kit according to the manufacturer’s instructions. Alternatively, the gel slice could be 
weight first and then frozen or kept at 4°C for later DNA extractions. 
 
5.1.5 Spectrophotometric quantification of nucleic acids 
To determine the concentration of a PCR product or plasmid DNA in a sample, the DNA was 
analysed using the NanoDrop® ND-1000, a spectrophotometer. The absorption was measured at 
260nm (absorption peak of nucleic acids). 
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5.1.6 Ligation of DNA fragments 
For the ligation of DNA fragments, linearised vector DNA and the digested and purified PCR 
product were connected with their compatible ends, using the T4 DNA ligase (Fermentas) according 
to the manufacturer’s instructions. The ligation reaction was performed using 50-100ng of vector 
DNA at a molar ratio of 1:3 or 1:5 (vector : insert). The respective DNA concentrations were assessed 
using the NanoDrop® ND-1000. For the ligation 5 Units of the T4 ligase (1µL in a final volume of 20µL) 
were added to the reaction mixture which was then incubated over night at 16°C. For inactivation of 
the T4 DNA ligase, the reaction mix was heated to 65°C for 10 min. The ligated plasmid was 
subsequently used for the transformation of competent Escherichia coli.  
 
5.1.7 Transformation and cultivation of chemically competent Escherichia coli (E. coli) 
The transformation of chemically competent bacteria (see section 4.14) was performed by 
adding 1µL of plasmid DNA or ligation reaction to 25µL of competent E. coli. The bacteria were 
incubated on ice for 20 min and then heat-shocked for 30-60 sec at 42°C, according to the antibiotic 
present in the vector backbone. After the heat-shock, the bacteria rested on ice for 15 min, were 
transferred into 250µL of pre-warmed SOC-medium and then incubated at 37°C and 550rpm for 1h. 
The transformed bacteria were subsequently plated on LB-agar plates containing the respective 
antibiotic and then incubated over night at 37°C to allow formation of single colonies. For the 
isolation and analysis of the clones, 2-5mL of LB-medium containing the respective antibiotic were 
inoculated with a plastic tip exposed to a single colony. The reaction tube was incubated for 5h or 
over night at 37°C to allow bacterial growth. 
 
5.1.8 Cryoconservation and reactivation of bacteria 
For long-term storage of transformed bacteria, 200µL of 87% glycerol were added to 800µL 
of bacterial culture and frozen at -80°C. In order to reactivate the bacteria, LB-medium containing the 
respective antibiotic was inoculated by scratching an adequate amount from the frozen bacteria 
culture with a plastic tip. This culture was then incubated over night at 37°C on a shaker. 
 
5.1.9 Plasmid DNA preparation and purification 
Isolation and purification of plasmid DNA from bacteria culture was performed using the 
PureLINK™ Quick Plasmid Miniprep Kit (Invitrogen) or the Qiagen Spin Miniprep Kit / Plasmid Midi Kit 
according to the manufacturer’s instructions. For cloning purposes and subsequent DNA sequencing, 
the plasmid DNA was isolated using the Miniprep kits. Here, 3-5mL of bacterial over night culture 
were used. The isolated DNA was then analysed by restriction enzyme digestion and verified by DNA 
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sequencing (GATC Biotech AG). For larger preparations of plasmid DNA, 150-200mL of bacteria 
culture were purified using the Qiagen Plasmid Midi Kit according to the manufacturer’s instructions. 
 
5.1.10 Cloning of HA-tagged and GST-tagged HPV E6 fusion proteins 
The pUC19 or pBR322 plasmids containing the complete viral HPV genomes of HPV4, 
HPV117, HPV118, HPV134 and HPV148 were kindly provided by Prof. Ingo Nindl (Charité, Berlin). The 
E6 genes were amplified by PCR (see section 5.1.1 and 4.10.1) to introduce the respective restriction 
sites and were ligated (see section 5.1.6) into the pGEX-4T1 vector for GST pull-down analysis or into 
the pPK-CMV-E3/pCMV3-Tag-1 vectors for transfection experiments in mammalian cells. 
 
5.2 Preparation and analysis of proteins 
 
5.2.1 Generation of whole cell protein extracts 
For Western blot analyses, whole cell protein extracts were prepared using the denaturing 
lysis buffer (see section 4.4). The buffer was freshly supplemented with protease and phosphatase 
inhibitors and MG-132. The cells were cultured on 6 or 10cm dishes, then detached from the culture 
dish and harvested into conical tubes. The cells were washed with 1x PBS by centrifugation (5 min, 
4°C, 2000rpm), resuspended in 100-200µL cold denaturing lysis buffer and kept on ice for 30 min. For 
lysis of the cellular membranes, the cell suspension was sonicated using the Sonifier 250 and 
subsequently the sample was centrifuged for 1h at 4°C and 13,000rpm. The supernatant containing 
the whole protein extract was collected in a fresh reaction tube and used to determine the protein 
concentration (see section 5.2.2). Subsequently, the protein extract was supplemented with 5x 
loading buffer, incubated at 95°C for 5 min and then stored at -80°C or directly analysed by Western 
blotting (see section 5.2.5).    
 
5.2.2 Protein quantification 
Proteins concentrations from whole cell extracts were measured using the BCA Protein Assay 
Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions [Smith et al., 1985]. The 
absorbance was measured at 570nm in a 96 well plate using an ELISA plate reader (Thermo Fisher 
Scientific). The protein concentration was determined on the basis of a standard curve applying 
0-2µg of BSA protein. The quantification of the GST-HPV E6 fusion proteins was performed using BSA 
standards of 0.5-10µg of BSA on a Coomassie-stained SDS-gel (see section 5.2.4).    
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5.2.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
For Coomassie staining or Western blot analysis, proteins had first to be separated on the 
basis of the discontinuous SDS-PAGE. This SDS-PAGE is a widely used method to separate proteins 
according to their electrophoretic mobility. It is based on a stacking gel and a separating gel forming 
a discontinuous gel system [Laemmli, 1970]. Proteins a separated during migration in the running gel 
according to their size. The extent of the separation depends on the respective polyacrylamide 
concentration. In this study, all proteins were separated in gels having a polyacrylamide 
concentration of either 10% or 12%. The gels were cats and run using the Mini-PROTEAN® system 
from Bio-Rad. 
              Table 5.2: Recipe for the preparation of stacking and resolving gels 
Resolving gel Stacking gel 
0.25M Tris/HCl pH 8.8 0.25M Tris/HCl pH 6.8 
10% or 12% Acrylamide-Bis (29:1) 5% Acrylamide-Bis (29:1) 
0.1% SDS 0.1% SDS 
0.05% APS 0.05% APS 
0.08% TEMED 0.16% TEMED 
 
Depending on the experimental setup, 50-80µg of total protein were loaded onto the gel for 
ideal signal detection. Before loading, the protein samples were supplemented with 5x protein 
loading buffer and incubated at 85°C or 95°C for 5 min. For a better readout, a protein size marker 
(Page Ruler™ Plus Prestained Protein Ladder) was added to the gel. The gels were run at 80V until the 
proteins reached the resolving gel. Then the voltage was increased to 120V until the desired protein 
resolution was achieved. 
 
5.2.4 Coomassie staining of polyacrylamide gels 
After SDS-PAGE, Coomassie staining was performed to visualise the proteins inside the gel. 
Therefore, the gel was incubated in fixing solution for 1h to mediate the coupling of the proteins to 
the gel. Subsequently, the gel was incubated in the Coomassie staining solution for 1h, where the 
fixed proteins were stained. After destaining for several hours or over night, the gels were dried 
using a vacuum gel dryer at 80°C for 50 min to facilitate a long-term storage or for subsequent 
autoradiographic exposures (see section 5.3.3).    
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5.2.5 Western blotting and protein detection 
Whole cell protein extracts or protein complexes were separated by SDS-PAGE and then 
detected using Western blot analysis. After SDS-PAGE, the proteins were electrophoretically 
transferred onto a PVDF membrane and probed with antigen-specific antibodies. The electrophoretic 
transfer was performed using a Wet blot Western chamber (Bio-Rad). First, the PVDF membrane was 
activated by incubation in methanol for 1 min and then equilibrated in 1x Towbin buffer together 
with the SDS-PAGE gel and two whatman papers. All components were arranged vertically between 
the electrodes of the Wet blot chamber according to the manufacturer’s instructions.  The transfer 
run was performed for at 4°C for 1h at 390mA under stirring on a magnetic mixer. The proteins 
immobilised on the PVDF membrane were visualised using antigen-specific primary antibodies and 
horseradish peroxidase (HRP)-conjugated secondary antibodies (see Tab. 4.10). To reduce unspecific 
binding of the applied antibodies, the PVDF membrane was incubated in blocking solution (5% milk 
powder/TBST or 5% BSA/TBST) after the protein transfer for 1h at room temperature or over night at 
4°C. Then, it was incubated with the primary antibody diluted in the respective blocking reagent for 
1h at room temperature or over night at 4°C, always depending on the manufacturer’s 
recommendations for the respective antibody. Next, the membrane was washed with 1x TBST for 10 
min several times and then incubated with the secondary HRP-conjugated antibody for 1h at room 
temperature, again followed by several washing steps. Finally, the specifically bound antibody 
complexes were detected using the enhanced chemiluminescence (ECL) reagents (Perkin Elmer and 
Thermo Fisher Scientific), which employs the HRP-catalysed chemiluminescence reaction for protein 
visualisation. Therefore, the membrane was incubated with the ECL reagent according to the 
manufacturer’s instructions. The bound antigen-specific antibodies were detected by 
autoradiography through exposition to X-ray films. The exposition time and the utilised ECL reagent 
strongly depended on the used antibody.  
 
5.2.6 Membrane stripping 
To allow the detection of different proteins of similar size on the same PVDF membrane, 
bound antigen-specific antibodies had to be removed. Therefore, the membrane was incubated for 
10 min in 0.2M NaOH and then washed for 5 min with ddH2O. The membrane was then incubated in 
blocking solution (5% milk powder/TBST or 5% BSA/TBST) for 1h and re-incubated with a different 
antigen-specific antibody as described in section 5.2.5. 
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5.3 In vitro assays 
 
5.3.1 In vitro transcription/translation of proteins 
For eukaryotic in vitro transcription/translation of proteins, the TNT® Coupled Reticulocyte 
Lysate System (Promega) was employed according to the manufacturer’s instructions. First, all 
needed reagents were thawed on ice. The plasmid DNA templates of Flag-p53 and its deletion 
mutants as well as the constructs of the putative interaction partners (PDCD6IP, LPXN, C9orf102 and 
Ajuba) were first diluted to a concentration of 0.5µg/µL. The reaction was performed using the 
provided TNT® T7 RNA Polymerase together with the following reagents in a 1.5mL reaction tube: 
 
25µL TNT® Rabbit Reticulocyte Lysate 
2µL TNT® Reaction Buffer 
1µL TNT® T7 RNA Polymerase 
1µL Amino Acid Mixture, Minus Methionine, 1mM 
2µL L-[35S]-methionine  
2µL RNase OUT 
2µL DNA template (0.5µg/µL) 
ad 50µL  Nuclease-free water 
 
The reaction mixture was mixed very gently by stirring it using a pipette tip and then 
incubated for 90 min at 30°C. Before the storage of the in vitro translated protein mixture at -80°C, a 
3µL aliquot was removed, supplemented with 30µL of 1x protein loading buffer and incubated at 
85°C for 5 min for the subsequent analysis of the translation efficiency. Therefore, an SDS-PAGE was 
performed loading the protein marker and the in vitro translated protein onto the gel. After the gel 
run it was analysed by Coomassie staining. Additionally, the gel was incubated in Amplify 
Fluorographic Reagent (GE Healthcare) for 15 min at 50°C, which increases the sensitivity of 
detection for weak beta emitters like 35S. Thereafter, the gel was dried using the vacuum gel dryer for 
1h at 80°C, The in vitro translated and 35S-radioactively labelled proteins were autoradiographically 
detected in an autoradiography cassette over night at -80°C. 
 
5.3.2 Expression and purification of recombinant fusion proteins 
The GST-tagged recombinant fusion proteins were produced by transformation of the E. coli 
strain Rosetta with the pGEX-4T1 vector containing the PDCD6 or HPV E6 ORFs. The bacteria 
pre-cultures were grown in 100mL LB-medium supplemented with 100µg/mL ampicillin and 34µg/mL 
chloramphenicol over night at 37°C. The next day, 400mL of LB-medium supplemented with 
antibiotics were added to the pre-culture and grown at 37°C until the OD600 reached a value of 0.5. 
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Protein expression was induced by adding 250µM IPTG to the culture and the bacteria were then 
incubated over night at 24°C on a rotating shaker. After cultivation the bacteria were pelleted at 
6,000rpm at 4°C by centrifugation and frozen for 30 min or over night at -80°C. The pellet was then 
thawed on ice and resuspended in 10mL ice-cold 1x PBS supplemented with 100µM PMSF. The 
suspension was homogenised twice by sonication using the Sonifier 250. The suspension was 
incubated on ice for 15 min after the addition of 1.5mL 10% Triton X-100/PBS. The homogenisation 
step was repeated and the cell debris collected by centrifugation (13,000rpm, 20 min, 4°C). The 
supernatant was then incubated with 300µL of PBS equilibrated Glutathione Sepharose™ 4FastFlow 
beads (GE Healthcare) under rotation for 6h at 4°C. The beads were collected by centrifugation at 
2,000rpm for 5 min at 4°C, washed twice with 10mL ice-cold 0.1% Triton X-100/PBS and once with 
cold 1x PBS to remove unspecifically bound proteins. The beads were then resuspended in 200µL 
1xPBS and analysed by SDS-PAGE and Coomassie staining in order to estimate the protein 
concentration of the purified recombinant fusion proteins. 
 
5.3.3 GST pull-down of recombinant GST-tagged HPV E6 fusion proteins 
GST pull-down experiments were performed to identify and thereby also confirm supposed 
direct interactions between two distinct proteins in vitro. For the GST pull-down 3µg (in a total 
volume of 30µL Glutathione Sepharose beads) of purified GST-HPV E6 fusion proteins (see section 
5.3.2) were incubated with 6µL of the in vitro transcribed and translated 35S-methionine labelled 
proteins (see section 5.3.1) in 500µL in vitro interaction buffer under rotation at 4°C for 90 min. After 
incubation, the beads were pelleted by centrifugation at 2,000rpm for 2 min and washed up to 10 
times with 750µL ice-cold in vitro interaction buffer to remove unspecifically bound proteins. The 
residual beads, containing the bound protein complexes were supplemented with 25µl of 1x protein 
loading buffer and incubated for 5 min at 85°C. The protein complexes were then separated by 
SDS-PAGE and the gel was stained with Coomassie. Additionally, the stained gel was incubated in 
Amplify Fluorographic Reagent (GE Healthcare) at 50°C for 15 min and then dried in a vacuum gel 
drier for 1h at 80°C, The radioactive signals were detected in an autoradiography cassette after an 
over night incubation at -80°C. 
 
5.4 In vivo co-immunoprecipitation of proteins 
Co-immunoprecipitation (Co-IP) analysis is a frequently used method to identify 
protein-protein interactions occurring in mammalian cells, by using target-specific antibodies. 
Therefore, cells were transfected in 6cm dishes with the respective plasmids using the Lipofectamine 
2000 reagent (Invitrogen) according to the manufacturer’s instructions (see section 5.5.3). 24h after 
transfection, the cells were harvested and washed with 1x PBS by centrifugation (2 min, 2000rpm). 
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The cell pellets were either frozen at -80°C or directly resuspended in 200µL ice-cold non-denaturing 
lysis buffer supplemented with protease and phosphatase inhibitors as well as MG-132. The cell 
suspension was incubated on ice for 1h to allow cell lysis and was subsequently centrifuged at 
10,000rpm for 1h at 4°C. The supernatant containing the whole protein extract was transferred into a 
fresh 1.5mL reaction tube. As input control, 5-30% of the supernatant were supplemented with 5x 
loading buffer, incubated at 85°C for 5 min and stored at -80°C until the SDS-PAGE. The residual 
protein suspension was filled to a volume of 500µL with pre-chilled non denaturing lysis buffer. For 
pre-clearing, the protein suspension was incubated with 30µL of Protein A/G PLUS-Agarose beads 
(Santa Cruz) for 1h at 4°C under rotation. To remove the beads, the protein suspension was 
centrifuged for 1 min and 6,000rpm at 4°C. The supernatant containing the cleared, unbound 
proteins was transferred into a fresh 1.5mL reaction tube. For co-precipitation itself, 1-5µg of a 
target-specific antibody was incubated with the protein extract for 3h at 4°C under rotation. After 
incubation, 30µL of Protein A/G PLUS-Agarose beads were added and additionally incubated for 1h at 
4°C. The protein suspension was centrifuged (1 min, 6,000rpm, 4°C), the supernatant discarded and 
the beads harbouring the specifically bound protein complexes were washed several times in cold 
non-denaturing lysis buffer to remove unspecifically bound proteins. At last, the beads were 
supplemented with 30µL of 1x protein loading buffer and incubated for 5 min at 85°C. The bound 
protein complexes as well as the stored input control were analysed by SDS-PAGE and subsequent 
Western blot analysis (see section 5.2.5). 
 
5.5 Cell culture 
 
5.5.1 Maintenance of mammalian cells 
Mammalian cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal calf serum (FCS). The cells were cultivated in cell culture flasks until they reached a 
confluency of 80-90% and were then passaged or seeded in new dishes for experiments. All cell lines 
were maintained at 37°C, 5% CO2 and 95% humidity in an incubator. For passaging, the culture 
medium was removed and the cells washed once with 1x PBS. In order detach adherent cells from 
the culture flasks they were incubated with 0.25% trypsin/EDTA solution and incubated at 37°C until 
they dissociated. The trypsin solution was inactivated by addition of DMEM containing 10% FSC. For 
cell maintenance, the cells were then transferred into fresh culture flasks at a ratio of 1:10 or 1:20, 
depending on their growth, and further incubated at 37°C. For experimental set-ups, the cells were 
first counted in a Neubauer hemocytometer. The required number of cells was transferred into 
culture flasks or dishes and incubated at 37°C. All cell lines were regularly checked for Mycoplasma 
contaminations. 
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5.5.2 Cryoconservation and reactivation of mammalian cells 
For long-term storage of eukaryotic cells in liquid nitrogen, 1x106 cells or the half of a 75cm2 
cell culture flask were pelleted by centrifugation at 2,500rpm for 5 min and washed with 1x PBS. The 
cells were then resuspended in 2mL cold freezing medium and transferred into cryo-tubes. The tubes 
were cooled down slowly using a cell freezer at -80°C. After several days, the cryo-tubes were 
transferred the liquid nitrogen tanks. To reactivate the cells, the frozen cryo-tubes were thawed 
rapidly at 37°C and transferred into 10mL of cultivation medium. The cells were pelleted by 
centrifugation and washed one with 1x PBS to remove residual DMSO. The cell pellets were then 
resuspended in fresh culture medium and transferred into cultivation flasks.  
 
5.5.3 Transfection of plasmid DNA into mammalian cells 
For transfection of plasmid DNA, 3x105 cells were seeded in 6 cm cell culture dishes one day 
prior to transfection or grown to a density of 70% confluence. All cell lines were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. The transfection 
reagent is lipid-based and encases the DNA thus facilitating the uptake into eukaryotic cells. The cells 
were transfected with 2-5µg of plasmid DNA and up to 10µL Lipofectamine 2000 reagent. The 
respective plasmid DNA was diluted in Opti-MEM. Subsequently, the Lipofectamine 2000 was diluted 
in Opti-MEM and incubated for 5 min at room temperature. The Lipofectamine solution was then 
added to the DNA suspension and mixed by inverting the reaction tube several times. The mixture 
was then incubated for 20 min at room temperature and applied evenly to the seeded cells. The cells 
were incubated for up to 48h prior to protein extraction for Western blot analysis (see section 5.2.5). 
 
5.5.4 Transfection of siRNA into mammalian cells 
Upon siRNA transfection, the genes of interest were silenced by the degradation of specific 
mRNA in mammalian cells. For siRNA-mediated knockdown of proteins, cells were seeded in 6 cm cell 
culture dishes one day prior to transfection and grown until a confluence of 30%. The cells were 
transfected with siRNA (Dharmacon) using Lipofectamine 2000 as described in 5.5.3. Here, 
100-200 pmoles of specific siRNA or scramble control siRNA were used. The cells were incubated 
with the respective siRNA for 48h and then repeatedly transfected. 96h after the first transfection, 
the cells were harvested and analysed by Western blotting (see section 5.2.5). 
 
5.5.5 Generation of stable cell lines 
For the generation of stable cell lines, the cells were transfected with 1µg of the respective 
expression plasmid using the Effectene transfection reagent (Qiagen) according to the 
manufacturer’s instructions. 24h after transfection the cells were transferred from a 6 cm culture 
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dish into a 75 cm2 cell culture flask and grown until 70% of confluence were reached. The medium 
was then supplemented with up to 850µg/mL of the antibiotic Geneticin (G418). In parallel, 
untransfected control cells were also treated with the same amount of G418. After two weeks of 
selection pressure, the drug resistant cells were considered “stably” transfected. However, the 
expression of the respective protein, stably introduced into the cells, was controlled by Western blot 
analysis.  
 
5.5.6 Adriamycin and UVB treatment 
For UVB irradiation, the cells were grown to a minimum of 60% confluence. The growth 
medium was removed and the cells washed once with 1x PBS, prior to irradiation with UVB using the 
Waldmann UV181 BL. The UVB dose was set to either 300 J/m2 or 1,000 J/m2 with an output range of 
280 to 320nm. Additionally, the amount of radiated UVB was measured with an UVB detector 
(Variocontrol UV-meter). After irradiation, the cells were supplemented with fresh growth medium 
and harvested after 24h. For Adriamycin treatment (ADR), the cells were grown as for the UVB 
irradiation. The growth medium was replaced to medium supplemented with ADR (1µg/mL) and the 
cells were incubated at 37°C and harvested at indicated time points for Western blot analysis. 
 
5.5.7 Immunofluorescence staining of mammalian cells 
For monitoring of the localisation of overexpressed or endogenous proteins, 
immunofluorescence staining was performed. All steps were performed at room temperature. First, 
the cells were grown on round cover slips in DMEM supplemented with 10% FCS. They were then 
transfected with the respective plasmids for 48h. After incubation, the cells were washed once in 1x 
PBS and fixed in 3.7% paraformaldehyde/PBS for 20. After fixation, the cells were washed once with 
0.1M glycine and subsequently permeabilised with 0.5% Triton X-100/PBS. The cells were incubated 
for 1h with 1% BSA/PBS prior to the addition of the primary antibodies for 90 min, which were 
diluted in 1% BSA/PBS. The cover slips were washed three times for 5 min in 1x PBS and incubated 
with specific fluorescein-conjugated secondary goat antibodies (Alexa Fluor®, Tab. 4.10) for 45 min. 
Additionally, all cover slips were incubated with Hoechst staining solution (1:10,000) for 20 min. The 
stained cells were then washed several times with 1x PBS and water and mounted on glass slides 
with Mowiol. The slides were dried over night in the dark and analysed by confocal microscopy. 
 
5.5.8 Luciferase reporter assay 
One day before transfection H1299 cells were plated in a density of 5x104/well of a 24-well 
plate. The following day, the cells were transfected with 5ng/well p53-promoter firefly luciferase 
reporter and 1ng/well of pRL-TATA renilla luciferase plasmid for normalisation. Additionally, the cells 
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were transfected with increasing amounts (0-5ng) of HA-tagged HPV23 E6 or HPV148 E6. 24h after 
transfection, the cells were lysed and firefly luciferase activity was analysed and normalised to renilla 
luciferase activity using the Dual Luciferase Reporter System (Promega) according to the 
manufacturer’s instructions. All experiments were performed four times in triplicates. 
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S e c t i o n 7 
 
Appendix 
 
7.1 Abbreviations 
 
A  
ActA ActA repeat region 
ADR Adriamycin 
AK Actinic keratosis 
ALV Avian leukemia virus 
aPKC Atypical protein kinase C 
APS Ammonium persulfate 
ATL Adult T-cell leukemia 
ATR Ataxia telangiectasia and Rad3-related protein 
  
B  
BCA Bicinchoninic acid 
BCC Basal cell carcinoma 
BSA Bovine serum albumin 
  
C  
CDS Coding DNA sequence 
CH Calponin homology 
CHK2 Checkpoint kinase 2 
CIN  Cervical intraepithelial neoplasia 
CMV Cytomegalovirus 
CO2 Carbon dioxide 
Co-IP Co-immunoprecipitation 
CRP Cysteine-rich protein 
CRPV Cottontail rabbit papilloma virus 
C9orf102 Chromosome 9 Open Reading Frame 102 
  
D  
ddH2O Double distilled water 
DKFZ German Cancer Research Centre 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTPs Deoxy nucleotide triphosphates 
  
E  
EBV Epstein-Barr virus 
ECL Enhanced Chemiluminescence Substrate 
E.coli Escherichia coli 
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EDTA Ethylenediaminetetraacetate 
e.g. Exempli gratia 
ELISA Enzyme-linked immunosorbent assay 
Ena/VASP Enabled/Vasodilator-stimulated phosphoprotein 
et al. Et alii 
EV Epidermodysplasia verruciformis 
E6AP E6-associated protein 
  
F  
FCS Fetal Calf Serum 
FHL Four-and-a-half LIM 
Fig. Figure 
  
G  
G418 Geneticin 
GFP Green fluorescent protein 
Grb2 Growth factor receptor-bound protein 2 
GST Glutathione S-transferase 
  
H  
h hour 
HA Haemagglutinin 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HD Homeodomain 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HEK Human Embryonic Kidney 
HHV Human herpesvirus 
HIPK2 Homeodomain-interacting protein kinase 2 
HPKn Neonatal human primary keratinocytes 
HPV Human papillomavirus 
HRP Horseradish peroxidase 
HTLV-1 Human T-cell lymphotropic virus 
  
I  
IF Immunofluorescence 
IgG (H+L) Immunoglobulin G (heavy and light chain) 
IP Immunoprecipitation 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
  
J  
J Joule 
  
K  
KSHV Kaposi’s sarcoma-associated herpesvirus 
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L  
LATS Large tumour suppressor 
LB Lysogeny broth 
LCR Long control region 
LD Leucine-aspartate domain 
LHX LIM-homeodomain protein 
LIM Lin11, Isl-1, Mec-3 
LIMD1 LIM domain-containing protein 1 
LIMK LIM kinase 
LMO LIM only protein 
LPP Lipoma preferred partner 
LPXN Leupaxin 
  
M  
MAP Mitogen-activated protein 
mg Milligram 
Mdm2 Mouse double minute 2 homolog 
MICAL Molecule interacting with CASL protein-1 
mL Millilitre 
µg Microgram 
µm Micrometre 
mRNA Messenger RNA 
  
N  
NES Nuclear export signal 
NIKS Normal immortal keratinocytes 
NMSC Non-melanoma skin cancer 
  
O  
OD optical density 
ORF open reading frame 
OTR Organ transplant recipient 
  
P  
p.a. pro analysi 
PAE Early polyadenylation site 
PAL Late polyadenylation site 
PARP Poly ADP ribose polymerase 
PBS Phosphate buffered saline 
pCMV Cytomegalovirus promoter 
PCR Polymerase chain reaction 
PDCD6 Programmed Cell Death 6 
PDCD6IP Programmed Cell Death 6 Interacting Protein 
PDZ Postsynaptic density-95, Discs large, Zona occludens-1 
PET Prickle, espinas, testin 
PINCH Particularly interesting new cysteine and histidine-rich protein 
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PMSF Phenylmethylsulfonyl fluoride 
pRb Retinoblastoma protein 
PRMT5 Protein arginine methyltransferase 5 
PTEN Phosphatase and tensin homolog 
PV Papillomavirus 
PVDF Polyvinylidene fluoride 
  
R  
RNA Ribonucleic acid 
RNAi RNA interference 
rpm Revolutions per minute 
RSV Rous sarcoma virus 
  
S  
SCC Squamous cell carcinoma 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS-Polyacrylamide gel electrophoresis 
SH3 Src-homology-3  
siRNA Small interfering RNA 
SOC Super optimal broth with glucose 
  
T  
Tab. Table 
TAE Tris base, acetic acid and EDTA 
TBS Tris-buffered saline 
TBST Tris-buffered saline/Tween20 
TEMED Tetramethylethylenediamine 
TMC Transmembrane channel-like 
TMV Tobacco mosaic virus 
TRAF6 Tumour necrosis factor receptor-associated factor 6 
Trip6 Thyroid hormone interacting protein 6 
  
U  
URR Upstream regulatory region 
UV Ultraviolet 
  
V  
V Volt 
v/v Volume percent 
  
W  
WHO World Health Organization 
WTIP Wilms tumour 1 interacting protein 
w/v Weight percent 
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XYZ…  
Y2H Yeast Two-Hybrid 
YFP Yellow fluorescent protein 
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